Back

Please find below the online abstract Poster Walks of the last EAHP Congresses.
Please select the desired annual Congress to view the posters presented in the different topic categories.

29th Congress of the EAHP

National Poster Prize Winners

Section 1: Introductory Statements and Governance

Section 2: Selection, Procurement and Distribution

Section 3: Production and Compounding

Section 4: Clinical Pharmacy Services

Section 5: Patient Safety and Quality Assurance

Section 6: Education and Research

28th Congress of the EAHP

National Poster Prize Winners

PDF Document	Poster Title	Poster Number
	EXTEMPORANEOUS FLUCYTOSINE 15,5% INTRAVAGINAL GEL TO TREAT REFRACTORY CANDIDA GLABRATA VULVOVAGINTIS – CASE REPORT	NP-001
	MEDICATION SAFETY: STRATEGIES & OPPORTUNITIES IN CLINICAL PHARMACY PRACTICE	NP-002
	PATIENT MEDICINE GUIDES SUPPORT SAFE MEDICATION TREATMENT AND DISCHARGE FROM THE HOSPITAL IN PAEDIATRIC SPECIALISED MEDICAL CARE	NP-003
	PALL-OLU.DE: A NEW DATABASE ON THE OFF-LABEL USE OF DRUGS IN PALLIATIVE MEDICINE	NP-004
	UNAUTHORISED MEDICATION USE IN ESTONIAN HOSPITALS	NP-005
	DRUGHOST, THE FIRST DATABASE OF UNAVAILABLE DRUGS IN EUROPE—AN ITALIAN MODEL: DATA ONE YEAR AFTER THE START OF THE PLATFORM	NP-006
	VALIDATION OF ANTIMICROBIAL DEFINED DAILY DOSE (DDD) FOR THE PAEDIATRIC POPULATION: FINAL RESULTS OF KIDDDS PROJECT	NP-007
	CASE REPORT : SINGLE-USE CRANIAL DRILLS, HIGH-RISK DEVICES!	NP-008
	BARRIERS AND FACILITATORS TO PHARMACY PROFESSIONALS’ SPECIALIST PUBLIC HEALTH SKILLS: A MIXED METHODS UK-WIDE PHARMACEUTICAL PUBLIC HEALTH EVIDENCE REVIEW	NP-009
	COMPATIBILITY OF LOCAL ANESTHETIC AND CORTICOSTEROID MIXTURES IN TRANSFORAMINAL EPIDURAL STEROID INJECTIONS	NP-010
	LINEZOLID THERAPEUTIC DRUG MONITORING AMONG CRITICALLY ILL ADULT PATIENTS AFTER CARDIOVASCULAR SURGERY	NP-011
	IMPROVING THE CLINICAL PHARMACIST HANDOVER PROCESS USING AN ADAPTED ISBAR COMMUNICATION TOOL WHEN TRANSFERRING PATIENTS FROM CORK UNIVERSITY MATERNITY HOSPITAL (CUMH) TO AN INTENSIVE CARE UNIT (ICU) WITHIN CORK UNIVERSITY HOSPITAL (CUH).	NP-012

Section 1: Introductory Statements and Governance

PDF Document	Poster Title	Poster Number
	ANALYSIS OF THE USE OF ORAL ONCOLOGY TARGETED THERAPIES IN A REGION OF SPAIN	1ISG-001
	PHARMACIST RISK STRATIFICATION: A CHARACTERISATION OF PATIENTS WITH LOW SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR WHO DIED WITHIN 90 DAYS OF HOSPITAL DISCHARGE	1ISG-002
	PHARMACIST RISK STRATIFICATION: A CHARACTERISATION OF PATIENTS WITH LOW SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR WHO DIED WITHIN 90 DAYS OF HOSPITAL DISCHARGE	1ISG-002
	DIGITAL TRANSFORMATION OF THE HOSPITAL/TERRITORIAL PHARMACY – TELEPHARMACY NEW DIMENSION OF PATIENT CARE MODELS	1ISG-003
	MULTIDISCIPLINARY MANAGEMENT OF CENTRAL VENOUS CATHETERS (CVCS) IN HEMODIALYSIS PATIENTS.	1ISG-004
	ASSESSMENT OF A MANAGEMENT TOOL REGARDING MEDICAL DEVICE VIGILANCE	1ISG-005
	ECONOMIC SAVING OF THE PREPARATION OF SUBCUTANEOUS FORMULATIONS COMPARED TO INTRAVENOUS: FOCUS ON DARATUMUMAB IN THREE HEALTHCARE COMPANIES	1ISG-006
	HTA ANALYSIS FOR THE INCLUSION OF ANDEXANET ALFA (AA) WITHIN THE HOSPITAL THERAPEUTIC HANDBOOK (HTH) – THE EXPERIENCE OF AN ITALIAN CENTER SPECIALIZING IN CARDIOVASCULAR DISEASES	1ISG-007
	USABILITY EVALUATION OF AN INSULIN MANAGEMENT SOLUTION WITHIN AN ELECTRONIC PATIENT RECORD	1ISG-008
	PHARMACOECONOMIC ANALYSIS OF AN ALTERNATIVE DOSAGE REGIMEN FOR PALIVIZUMAB	1ISG-009
	ECONOMIC IMPACT OF THE CLINICAL PHARMACIST ON THE REDUCTION OF DRUG-RELATED PROBLEMS BEFORE THE INITIATION OF AN ANTI-TUMOR TREATMENT – A PROSPECTIVE MULTICENTER TRIAL	1ISG-010
	OPPORTUNITY FOR DAILY HOME-BASED MANAGEMENT OF CHRONIC PATIENTS FROM THE SAME AREA USING AN INTERPROFESSIONAL NETWORK MODEL DEVISED, SET UP AND IMPLEMENDET FOR THE COVID-19	1ISG-011
	BALANCING CLINICAL BENEFITS AND COST SAVINGS: COMPASSIONATE DRUG USE AT AN ITALIAN UNIVERSITY HOSPITAL – EVIDENCE AND INSIGHTS	1ISG-012
	BALANCING CLINICAL BENEFITS AND COST SAVINGS: COMPASSIONATE DRUG USE AT AN ITALIAN UNIVERSITY HOSPITAL – EVIDENCE AND INSIGHTS	1ISG-012
	REAL-LIFE DATA OF CDK4/6 INHIBITORS PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN LOCALLY ADVANCED OR METASTATIC BREAST CANCER: EFFECTIVENESS EVALUATION	1ISG-013
	SUSTAINABLE HEALTHCARE: AN EXAMPLE OF PHARMACEUTICAL INTERVENTION	1ISG-014
	ASSESSMENT OF PREPARATORY STAFF’S KNOWLEDGE OF CARCINOGENIC, MUTAGENIC AND REPROTOXIC (CMR) RISKS	1ISG-015
	OCRELIZUMAB FOR THE TREATMENT OF RECAPTING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN NATIONAL HEALTH SYSTEM: A COST EFFECTIVENESS ANALYSIS	1ISG-016
	THE THREE HORIZONS METHOD AS A TOOL FOR DEFINING THE HOSPITAL PHARMACY RESIDENT OF THE FUTURE(HPRF)	1ISG-017
	TEN-YEAR DRUG SURVIVAL ANALYSIS IN MODERATE TO SEVERE PLAQUE PSORIASIS FIRST-LINE TREATMENT	1ISG-018
	DO ALL SURGICAL SPECIALTIES HAVE AN IDENTICAL CARBON FOOTPRINT WHITIN AN AMBULATORY UNIT ?	1ISG-019
	DRUG DAY THERAPY APPLIED TO LUSPATERCEPT: RESULTS OBTAINED IN AN ITALIAN ANTIBLASTIC DRUG UNIT	1ISG-020
	DRUG DAY THERAPY APPLIED TO LUSPATERCEPT: RESULTS OBTAINED IN AN ITALIAN ANTIBLASTIC DRUG UNIT	1ISG-020
	1 YEAR-REVIEW OF THE EKOSONIC® ENDOVASCULAR SYSTEM (BOSTON SCIENTIFIC) IN THE MANAGEMENT OF PULMONARY EMBOLISM IN AN INTERVENTIONAL CARDIOLOGY DEPARTMENT	1ISG-021
	HOSPITAL PHARMACISTS’ PERCEPTIONS OF THEIR PROFESSION IN TWO EUROPEAN COUNTRIES	1ISG-022
	ECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL	1ISG-023
	ECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL	1ISG-023
	SINGLE-USE MEDICAL DEVICES IN THE TREATMENT OF CHRONIC DISEASES: WHAT IS THE ENVIRONMENTAL IMPACT?	1ISG-024
	ANALYSIS OF THE COMPLEXITY OF THE CLINICAL TRIALS CARRIED OUT IN A THIRD-LEVEL HOSPITAL	1ISG-025

Section 2: Selection, Procurement and Distribution

PDF Document	Poster Title	Poster Number
	CLINICAL IMPACT AND COST SAVINGS OF AN OUTPATIENT ANTIMICROBIAL THERAPY PROGRAMME: A FOCUS ON SELF-ADMINISTRATION	2SPD-001
	EVALUATION OF THE EFFECTIVENESS AND RELATED COST OF ONCOLOGY DRUGS USED IN SPECIAL SITUATIONS, IN A THIRD-LEVEL UNIVERSITY HOSPITAL	2SPD-002
	PROPER MANAGEMENT AND ECONOMIC BURDEN OF UNUSED MEDICATIONS DISPOSAL IN A SUSTAINABLE LATIN AMERICAN HOSPITAL: A RETROSPECTIVE STUDY	2SPD-003
	BUDGETARY IMPACT OF THE INTRODUCTION OF CABOTEGRAVIR PLUS RILPIVIRINE LONG-ACTING IN A THIRD LEVEL HOSPITAL	2SPD-004
	ALTERNATIVE TO THE TREATMENT OF POOR GRAFT FUNCTION AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION: ELTROMBOPAG	2SPD-005
	IMPACT AND CONSEQUENCES OF THE USE OF HUMAN POLYVALENT IMMUNOGLOBULIN DURING THE COVID-19 PANDEMIC (2019-2022)	2SPD-006
	USE AND COST EVOLUTION OF ADALIMUMAB OVER EIGHT YEARS IN A LOCAL HOSPITAL	2SPD-007
	SWITCHING TO A BIOSIMILAR ADALIMUMAB IN DUTCH UNIVERSITY MEDICAL CENTERS: IT IS NOT THAT HARD!	2SPD-008
	A FIVE-YEAR RETROSPECTIVE REPORT ON COMPREHENSIVE MEDICINE PROCUREMENT WITHIN A PUBLIC GROUP PROCUREMENT ORGANISATION	2SPD-009
	IDENTIFYING AND QUANTIFYING DRUG-RELATED WASTE IN A HEALTHCARE ESTABLISHMENT	2SPD-010
	AVAILABILITY OF LIQUID ANTIMICROBIALS – A NATIONAL ANALYSIS OF THE CURRENT SUPPLY SITUATION	2SPD-011
	APPLICATION OF FAILURE MODE AND EFFECTS ANALYSIS TO IMPROVE AUTOMATED DISPENSING CABINETS’ DRUG STOCK MANAGEMENT PROCESSES	2SPD-012
	A COMPARATIVE LIFE CYCLE ASSESSMENT OF DIFFERENT PACKAGING OPTIONS FOR ALBUMIN DISTRIBUTION	2SPD-013
	ECO-CONSCIOUS HEALTHCARE PRODUCTS SUPPLY: INVESTIGATING THE EFFECTS OF FEWER ORDERS	2SPD-014
	INTEGRATED HEALTHCARE LOGISTICS: KANBAN SOLUTION FOR MANAGEMENT OF DIALYSIS WAREHOUSES PILOT CASE	2SPD-015
	DATA-DRIVEN SELECTION OF A MEDICATION MANAGEMENT MODEL IN HOSPITALISATION WARDS	2SPD-016
	RISK IDENTIFICATION IN ANTIDOTE AND EMERGENCY PREPAREDNESS	2SPD-017
	IMPACT OF INHALERS ON CO2 EMISSION IN A HEALTH AREA	2SPD-018
	TOWARDS A SUSTAINABLE OPERATING ROOM : FEEDBACK ON ACTIONS CARRIED OUT AROUND MEDICAL DEVICES	2SPD-019
	DESIGN AND EVALUATION OF AN INNOVATIVE AIRBORNE TRANSPORT SYSTEM FOR BLOOD-DERIVED DRUGS UNDER EMERGENCY CONDITIONS	2SPD-020

Section 3: Production and Compounding

PDF Document	Poster Title	Poster Number
	TOPICAL COMPOUNDED CLINDAMYCIN SOLUTION MADE FROM ORAL DOSAGE FORMS, CONTROL AND STABILITY STUDY	3PC-001
	STABILITY OF TENECTEPLASE SYRINGES AFTER FRACTIONATION	3PC-002
	SUITABILITY OF ELASTOMERIC PUMPS FOR DRUG STORAGE	3PC-003
	DRUG WASTE OF READY-TO-ADMINISTER SYRINGES IN THE INTENSIVE CARE UNIT: ASEPTICALLY PREPARED SYRINGES VERSUS PREFILLED STERILISED SRYINGES	3PC-004
	PREPARATION OF EPICUTANEOUS TESTS WITH MINOXIDIL AT 2% AND 5%.	3PC-005
	STABILITY STUDY OF CLOBAZAM LIQUID ORAL FORMS FOR PEDIATRIC PATIENTS	3PC-006
	CONTAINMENT PERFORMANCE ASSESSMENT OF CHEMFORT® (ONGUARD®2) CLOSED SYSTEM TRANSFER DEVICE ACCORDING TO 2016 DRAFT NIOSH PROTOCOL AT FIRST AND TENTH ACTIVATIONS END OF SHELF LIFE.	3PC-007
	STABILITY OF PARENTERAL NUTRITION ADMIXTURES: FOCUS ON PRECIPITATION.	3PC-008
	THE EFFECT OF ACCELERATED LIGHT (STRESS) AND NATURAL SUNLIGHT EXPOSURES ON CETUXIMAB (ERBITUX®): EVALUATION OF AGGREGATE FORMATION AND FUNCTIONALITY	3PC-009
	DEVELOPMENT OF A STABLE PARENTERAL SOLUTION OF TOPIRAMATE FOR EMERGENCY TREATMENT OF STATUS EPILEPTICUS	3PC-010
	MUCOSECTOMY : FEASIBILITY STUDY OF THE AUTOMATED PREPARATION OF A STERILE SOLUTION OF 5/10% FRUCTOSE GLYCEROL.	3PC-011
	CONTENT UNIFORMITY OF SODIUM BENZOATE CAPSULES: VALIDATION OF A METHOD USING QCPREP®	3PC-012
	RADIOPHARMACEUTICAL SINGLE-VIAL COLD KIT FORMULATION OF FAPI-04, AN EXPERIMENTAL VECTOR FOR GALLIUM-68 PET IMAGING IN ONCOLOGY	3PC-013
	PHYSICOCHEMICAL STABILITY OF BEVACIZUMAB 25 MG/ML CONCENTRATE (VEGZELMA®) IN ORIGINAL GLASS VIALS AFTER FIRST OPENING	3PC-014
	MICROBIOLOGICAL PERFORMANCE QUALIFICATION OF THE ROBOTIC SYSTEMS APOTECASYRINGE AND APOTECAUNIT	3PC-015
	PHYSICOCHEMICAL STABILITY OF MOXIFLOXACIN 1 MG/0,2 ML SYRINGES FOR INTRACAMERAL ADMINISTRATION	3PC-016
	ELABORATION OF DEFEROXAMINE EMULSION 0.5% FOR HYPERPIGMENTATION DUE TO INTRAVENOUS IRON EXTRAVASATION	3PC-017
	GLASS AMPOULE HANDLING PRACTICES IN DUTCH HEALTHCARE: A COMPREHENSIVE ASSESSMENT	3PC-018
	DEVELOPMENT A TOPICAL EMULSION FOR THE TREATMENT OF THIRD-DEGREE BURN PATIENTS CANDIDATES FOR SKIN GRAFT	3PC-019
	PREVENTION OF INFECTIOUS RISK IN PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ALPHA INHIBITORS (ANTI-TNFΑ)	3PC-020
	FORMULATION OF VORICONAZOLE OVULES AND EFFICACY IN VULVOVAGINAL CANDIDIASIS BY CANDIDA GLABRATA: A CASE REPORT.	3PC-021
	DESIGN AND STABILITY STUDY OF AN ISONIAZID AND PYRIDOXINE ORAL LIQUID FORMULATION	3PC-022
	NEW ACTIVITIES WITHIN A CLINICAL TRIAL MANAGEMENT UNIT: WHAT NEW RISKS FOR THE STAFF?	3PC-023
	IMPLEMENTATION OF A STRATEGY TO OVERCOME THE POTENTIAL TOXIC EFFECTS OF PROPYLENE GLYCOL IN NEONATES	3PC-024
	STABILITY STUDY OF STANDARDISED FLUID THERAPY PREPARED BY THE PHARMACY DEPARTMENT TO TREAT PEDIATRIC DIABETIC KETOACIDOSIS	3PC-025
	COST SAVINGS ASSOCIATED WITH ROMIPLOSTIM REPACKAGING IN PATTIENT WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA	3PC-026
	USE OF AUTOMATED COMPOUNDING DEVICES IN PEDIATRIC PARENTERAL NUTRITION: A GOOD WAY TO ENSURE SAFETY	3PC-027
	FOR A MORE ECONOMICAL AND ECOLOGICAL CENTRAL STERILE SERVICES DEPARTMENT (CSSD) : BACK TO THE CONTAINER	3PC-028
	PH MEASUREMENT: NOT AS SIMPLE AS WE THINK? A CASE OF SODIUM PERCHLORATE INJECTIONS	3PC-029
	STABILITY STUDY OF AN EPIDURAL ANALGESIC CONCENTRATE FOR INFUSION USED DURING CHILDBIRTH	3PC-030
	USABILITY OF SEMI-SOLID EXTRUSION 3D PRINTING IN HOSPITAL PHARMACY SETTINGS TO PRODUCE PERSONALISED ORAL MEDICATIONS FOR PEDIATRIC PATIENTS	3PC-031
	OPTIMIZATION OF AN INSULIN 1 IU/ML EYE DROP FORMULATION FOR THE TREATMENT OF CORNEAL ULCERS	3PC-032
	KIRO ISOLATOR®: A NEW, RELIABLE, ROBOTIC DEVICE FOR THE COMPOUNDING OF INJECTABLE ANTICANCER DRUGS	3PC-033
	FORMULATION OF KETAMINE 1% AND AMITRIPTYLINE 1% GEL IN PRURITIC EPIDERMOLYSIS BULLOSA: A CASE REPORT	3PC-034
	PATCH TESTS WITH HAZARDOUS DRUGS: IS IT POSSIBLE TO ENSURE SAFETY DURING PRODUCTION?	3PC-035
	RISK ANALYSIS OF THE PHARMACEUTICAL CIRCUIT FOR INJECTABLE CHEMOTHERAPIES AFTER IMPLEMENTATION OF DRUGLOG ®.	3PC-036
	ALUMINIUM IN PEDIATRIC PARENTERAL NUTRITION: ARE MULTICHAMBER-BAGS THE SAFER CHOICE?	3PC-037
	AUTOLOGOUS SERUM EYE DROPS PREPARATION: APPROACH TO THE FILTRATION STEP IMPACT ON THE CONCENTRATION OF ACTIVE MOLECULES	3PC-038
	EARLY DE-RISKING OF THE STABILITY OF A PERSONALISED, STERILE BACTERIOPHAGE SUSPENSION ON THE BASIS OF ADVANCED KINETIC MODELING	3PC-039
	RADIOCHEMICAL PURITY DETERMINATION OF 177LU-PSMA-617: DEVELOPMENT AND VALIDATION OF A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYTICAL METHOD	3PC-040
	PUBLIC PRODUCTION OF THERAPEUTIC BACTERIOPHAGES	3PC-041
	STERILE AND NON-STERILE COMPOUNDING: RISK ANALYSIS AND IMPROVEMENT MEASURES	3PC-042
	INTRAVITREAL PREPARATION OF LIPOSOMAL B AMPHOTERICIN: FROM FORMULATION STUDY TO PREPARATION	3PC-043
	A PHYSICO-CHEMICAL STABILITY STUDY OF VANCOMYCIN EYE DROP AFTER DIFFERENT THAWING TIMES	3PC-044
	RETROSPECTIVE STUDY OVER 6 YEARS OF THE TREND IN FUNGAL CONTAMINATION OF CONTROLLED ATMOSPHERE AREAS WITHIN A CELL THERAPY UNIT.	3PC-045
	RISK OF PERSONNEL EXPOSURE TO HAZARDOUS DRUGS IN ROBOTIC COMPOUNDING	3PC-046
	PEDIATRIC IV ANTIFUNGAL ADMIXTURES: CENTRALISATION’S ECONOMIC CONSEQUENCES	3PC-047

Section 4: Clinical Pharmacy Services

PDF Document	Poster Title	Poster Number
	COMPARATIVE ANALYSIS OF TWO PHARMACOKINETIC PROGRAMMES FOR LITHIUM ADJUSTMENT	4CPS-001
	PHARMACEUTICAL CARE IN POSTOPERATIVE PAIN MANAGEMENT AT ADMISSION AND DISCHARGE	4CPS-002
	EVALUATION OF CLINICAL VARIABLES IMPACT ON ENOXAPARIN DOSING AND ANTIXA CONCENTRATION	4CPS-003
	IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS	4CPS-004
	DRUG PERSISTENCE OF JAK INHIBITORS COMPARED TO BIOLOGIC DRUGS IN REAL-WORLD PRACTICE IN PATIENTS WITH RHEUMATOID ARTHRITIS	4CPS-005
	ADHERENCE TO NEBULIZED ANTIBIOTICS IN CYSTIC FIBROSIS PATIENTS AFTER STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR	4CPS-006
	ADALIMUMAB IN THE TREATMENT OF RECALCITRANT SWEET SYNDROME: A CASE REPORT	4CPS-007
	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO ANTITHROMBOTIC DRUGS IN EMERGENCY DEPARTMENT	4CPS-008
	NEONATAL DIAGNOSIS AND TREATMENT OF STIFF BABY SYNDROME: A CASE REPORT	4CPS-009
	CAN ERENUMAB IMPROVE QUALITY OF LIFE PERCEIVED BY PATIENTS?	4CPS-010
	REAL-WORLD EFFECTIVENESS AND SURVIVAL OF GUSELKUMAB IN PATIENTS WITH PSORIASIS AND PSORIASIC ARTRHITIS: MULTICENTER ANALYSIS IN DAILY CLINICAL PRACTICE BY THE VALENCIAN COMMUNITY PSORIASIS GROUP.	4CPS-011
	IMPROVING PARENTAL MEDICATION LITERACY BY PHARMACIST-LED DISCHARGE COUNSELLING IN PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION	4CPS-012
	INTRAVENOUS LEVETIRACETAM SUPPLETION DURING HAEMODIALYSIS PRESERVED STABLE THERAPEUTIC SERUM CONCENTRATIONS: A CASE REPORT	4CPS-013
	REAL WORLD DATA ON THE USE OF PCSK9 INHIBITOR TREATMENTS IN HYPERCHOLESTEROLEMIA	4CPS-014
	ASSESSMENT OF IN-HOSPITAL ANTIBIOTICS CONSUMPTION PATTERN ACCORDING TO THE WHO AWARE CLASSIFICATION IN A LOCAL HEALTH AUTHORITY	4CPS-015
	EXPERIENCES, VIEWS AND ATTITUDES OF HOSPITAL NURSING STAFF TOWARDS THE IMPLEMENTATION OF THE UNIT DOSE DISPENSING SYSTEM FOR INPATIENTS: A QUALITATIVE INTERVIEW STUDY	4CPS-016
	COMPARATIVE STUDY BETWEEN TIXAGEVIMAB/CILGAVIMAB AND SOTROVIMAB IN PATIENTS WITH COVID-19: A MONOCENTRIC EXPERIENCE AT UNIVERSITY HOSPITAL	4CPS-017
	SWITCHING BETWEEN CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN THE PROPHYLAXIS OF MIGRAINE	4CPS-018
	DIFFERENCES IN MEROPENEM DOSE ADJUSTMENT WITH CALCULATION OF GLOMERULAR FILTRATION RATE THROUGH DIFFERENT FORMULAS.	4CPS-019
	EVALUATION OF THE EFFECTIVENESS OF MONOCLONAL ANTIBODIES AGAINST MIGRAINE HEADACHE	4CPS-020
	PERFORMANCE OF MULTIPLE TRIGGER TOOLS IN IDENTIFYING MEDICATION-RELATED HOSPITAL READMISSIONS	4CPS-021
	THE EFFECT OF DIGITAL CLINICAL DECISION SUPPORT ON PHARMACOTHERAPY IN HOSPITALISED (MORBIDLY) OBESE PATIENTS: A PROSPECTIVE INTERVENTION STUDY	4CPS-022
	OPTIMISING BIOLOGIC THERAPY IN SEVERE UNCONTROLLED ASTHMA PATIENTS ON OMALIZUMAB TREATMENT	4CPS-023
	ANALYSIS OF POLYMEDICATION AND ADEQUACY TREATMENT RECOMMENDATIONS IN PATIENTS WITH MULTIPLE SCLEROSIS IN A TERTIARY LEVEL HOSPITAL.	4CPS-024
	MANAGEMENT OF COVID-19 WITH NIRMATRELVIR/RITONAVIR AND TACROLIMUS MONITORING IN RENAL TRANSPLANTATION: A CASE REPORT	4CPS-025
	ACCEPTABILITY AND WILLINGNESS TO SWITCH ANTIRETROVIRAL TREATMENT IN PATIENTS WITH LONG-ACTING INJECTABLE THERAPY CRITERIA.	4CPS-026
	ANALYSIS OF CARDIOVASCULAR RISK ASSOCIATED WITH IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE TREATMENT IN PATIENTS WITH CHRONIC LYMPHOID LEUKEMIA	4CPS-027
	ANALYSIS OF INTERACTIONS DETECTED IN THE CONCOMITANT USE OF ANTINEOPLASTIC AGENTS AND PHYTOTHERAPY IN ONCOHEMATOLOGY PRACTICE AND INTERVENTIONS CARRIED OUT.	4CPS-028
	USE OF TOPICAL 1% CIDOFOVIR ON SKIN LESIONS IN A PATIENT WITH MONKEYPOX	4CPS-029
	ANALYSIS OF ADHERENCE TO GROWTH HORMONE TREATMENT IN PAEDIATRIC PATIENTS.	4CPS-030
	A POPULATION PHARMACOKINETIC MODEL OF VEDOLIZUMAB IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PRELIMINARY ANALYSIS	4CPS-031
	PHARMACEUTICAL INTERVENTIONS FOR MEDICATION RECONCILIATION IN COMPLEX CHRONICALLY ILL PATIENTS	4CPS-032
	REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF SELECTIVE CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITORS UTILISATION IN METASTATIC BREAST CANCER – REVEAL STUDY	4CPS-033
	REAL-WORLD SAFETY AND TOLERABILITY IN PATIENTS TREATED WITH ABEMACICLIB AND ENDOCRINE THERAPY: A RETROSPECTIVE OBSERVATIONAL STUDY	4CPS-034
	IMPACT OF ANTIBIOTIC STEWARDSHIP PROGRAMME (ASP) ON ANTIBIOTIC USE AND CLINICAL OUTCOMES IN PATIENTS HOSPITALISED WITH COMMUNITYACQUIRED PNEUMONIA (CAP): RETROSPECTIVE OBSERVATIONAL BEFORE-AFTER STUDY	4CPS-035
	EVALUATION OF THE DIAGNOSIS AND ANTIBIOTIC PRESCRIPTION PATTERN IN PATIENTS HOSPITALISED WITH URINARY TRACT INFECTIONS (UTIS)	4CPS-036
	INTEGRATION OF THE PHARMACIST IN THE MULTIDISCIPLINARY COMMITTEE OF URO ONCOLOGICAL PATHOLOGY	4CPS-037
	CASE REPORT ON AUTONOMIC NEUROPATHY INDUCED BY BORTEZOMIB	4CPS-038
	DRUG-RELATED PROBLEMS AT HOSPITAL ADMISSION IN ELDERLY PATIENTS WITH CARDIOVASCULAR DISEASES	4CPS-039
	ADHERENCE TO GUIDELINES AND PRESCRIBING TRENDS OF STATINS IN PATIENTS WITH ACUTE CORONARY SYNDROME	4CPS-040
	SILENCE SPEAKS LOUDER THAN WORDS: OMISSION OF PRESCRIPTION IN THE EMERGENCY ROOM	4CPS-041
	OVERDOSE OF DARBEPOETIN IN PATIENTS WITH CHRONIC KIDNEY FAILURE. ROOM FOR IMPROVEMENT WITH PHARMACIST INTERVENTIONS	4CPS-042
	EFFICACY AND SAFETY OF ANTI-CALCITONIN GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES FOR MIGRAINE PROPHYLAXIS: ONE-YEAR REAL-LIFE EXPERIENCE	4CPS-043
	PRE-EXPOSURE PROPHYLAXIS DROP-OUT: FOLLOW-UP AND RELINKING THROUGH TELEPHONE CONTACT	4CPS-044
	OPTIMISATION OF OMALIZUMAB FOR SEVERE ALLERGIC ASTHMA IN PEDIATRIC POPULATION	4CPS-045
	EVALUATION OF HEALTH IMPACT IN INFLIXIMAB-TREATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: INCORPORATION OF PATIENT REPORTED OUTCOME MEASURES (PROMS)	4CPS-046
	EVALUATION OF ANTIRESORPTIVE AGENT-RELATED OSTEONECROSIS THERAPY BY MEASURING CONCENTRATIONS OF PENICILLIN G IN JAWBONE	4CPS-047
	A COMPLEX, ADHERENCE-IMPROVING PHARMACIST INTERVENTION TO REDUCE HYPERPHOSPHATEMIA IN HEMODIALYSIS PATIENTS	4CPS-048
	TREATMENT OF ROSAI DORFMAN’S HISTIOCYTOSIS: CASE REPORT	4CPS-049
	PRE-EXPOSURE PROPHYLAXIS FOR HIV INFECTION: PREVALENCE OF SEXUALLY TRANSMITTED INFECTIONS (STIS) AND ADHERENCE DURING THE PROGRAMME	4CPS-050
	COST SAVING IMPACT OF BIOSIMILAR TRASTUZUMAB FOR THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN A HOSPITAL	4CPS-051
	EVALUATION OF USTEKINUMAB USE IN INFLAMMATORY BOWEL DISEASES	4CPS-052
	OUTCOMES OF INFRADOSED ANTIMICROBIALS PATIENTS WITH BACTEREMIA IN THE EMERGENCY DEPARTMENT	4CPS-053
	NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES FOR MODERATE TO SEVERE ULCERATIVE COLITIS	4CPS-054
	PHARMACOGENETICS AND ITS APPLICATIONS IN PERSONALISED MEDICINE: A SYSTEMATIC REVIEW	4CPS-055
	EFFECTIVENESS AND SAFETY OF ERIBULIN THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER.	4CPS-056
	EFFECTIVENESS, SAFETY, AND PATIENT-REPORTED OUTCOME OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE	4CPS-057
	ANALYSIS OF ANTIFUNGAL CONSUMPTION IN AN INTENSIVE CARE UNIT OVER 5 YEARS	4CPS-058
	SEVENTEEN DRUGS, ONE SAMPLE: ANALYSING MULTIPLE ANTI-TUBERCULOSIS DRUGS SIMULTANEOUSLY USING ONE METHOD	4CPS-059
	IMPACT OF OBESITY ON VANCOMYCIN PHARMACOKINETIC PARAMETERS IN ADULT PATIENTS	4CPS-060
	SAFETY AND EFFECTIVENESS OF THE OFF-LABEL USE OF CANGRELOR IN PERIOPERATIVE BRIDGING: A CASE SERIES	4CPS-061
	POSITIVE IMPACT OF EXTENDING NATALIZUMAB DOSAGE INTERVAL FROM EVERY 4 WEEKS TO EVERY 6 WEEKS IN MULTIPLE SCLEROSIS PATIENTS	4CPS-062
	CLINICAL PHARMACIST IN THE MULTIDISCIPLINARY TEAM IN THE INTENSIVE CARE UNIT IMPROVE THE QUALITY OF MEDICINE THROUGHOUT THE PATIENT’S HOSPITAL STAY	4CPS-063
	REVIEW OF USE OF IMMUNOGLOBULINS IN TERTIARY HOSPITAL	4CPS-064
	EXPERIENCE OF IMMUNOCHEMOTHERAPY VERSUS STANDARD TREATMENT IN SMALL-CELL LUNG CANCER	4CPS-065
	THERAPEUTIC DRUG MONITORING OF ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE.	4CPS-066
	EFFECTIVENESS AND SAFETY OF 1 IU/ML TOPICAL INSULIN TO TREAT PERSISTENT CORNEAL ULCERS	4CPS-067
	TARGET THERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE ANALYSIS TO GUARANTEE THE APPROPRIATENESS OF THE PRESCRIPTIONS IN OUR HOSPITAL	4CPS-068
	OUTPATIENT SATISFACTION IN THE TELEPHARMACY PROGRAMME OF A TERTIARY HOSPITAL PHARMACY SERVICE	4CPS-069
	EVALUATION OF AVOIDED COST IN CLINICAL TRIALS WITH IMMUNOTHERAPY IN LUNG CANCER	4CPS-070
	ANTIBIOTIC CONSUMPTION MONITORING BY AWARE CLASSIFICATION: A SIX MONTHS ANALYSIS	4CPS-071
	SETMELANOTIDE IN MONOGENIC OBESITY: A CASE REPORT	4CPS-072
	ANALYSIS OF THE REASONS FOR CHANGING TREATMENT IN PATJENTS WITH MULTIPLE SCLEROSIS	4CPS-073
	DRUG CLASSES COMMONLY RELATED TO MEDICATION ERRORS AT TRANSITION OF CARE	4CPS-074
	A SYSTEMATIC REVIEW OF THE TARGET PHARMACOKINETIC/PHARMACODYNAMIC PARAMETERS OF ANTIBIOTICS TREATING GRAM-NEGATIVE INFECTIONS	4CPS-075
	EFFECTIVENESS AND SAFETY OF DUPILUMAB AND TRALOKINUMAB IN ATOPIC DERMATITIS IN CLINICAL PRACTICE	4CPS-076
	PHARMACEUTICAL INTERVENTIONS AFTER DETECTION OF NON-HANDLING MEDICATIONS IN PATIENTS WITH DYSPHAGIA	4CPS-077
	QUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES WITH MULTIPLE MYELOMA TREATEDS WITH DARATUMUMAB	4CPS-078
	INDIRECT COMPARISON OF IL-13 INHIBITORS PLUS TOPICAL CORTICOSTEROIDS IN MODERATE TO SEVERE ATOPIC DERMATITIS	4CPS-079
	METASTATIC HER2-POSITIVE BREAST CARCINOMA CASE REPORT: ANTI-HER2 TREATMENT MAINTENANCE DESPITE OLIGOPROGRESSION	4CPS-080
	CONSENSUS ON INDICATORS FOR MEDICATION-RELATED READMISSIONS: A DELPHI STUDY	4CPS-081
	DESCRIPTIVE STUDY OF POST-SURGERY ANALGESIC PRESCRIPTIONS	4CPS-082
	MEDICATION RECONCILIATION INTERVENTIONS IN AN EMERGENCY DEPARTMENT AT ADMISSION	4CPS-083
	GENOTYPING ANALYSIS OF POLYMORPHISMS IN THE DIAHYDROPYRHYDROMIDINE DEHYDROGENASE (DPYD) GENE PRIOR TO ADMINISTRATION OF FLUOROPIRMIDINES	4CPS-084
	LONG-TERM PERSISTENCE IN PSORIASIS PATIENTS WITH HIGH RESPONSE TO GUSELKUMAB: A REAL-WORLD RETROSPECTIVE STUDY.	4CPS-085
	ASSESSMENT OF THE CLINICAL RELEVANCE OF LEVETIRACETAM MONITORING	4CPS-086
	ADALIMUMAB PERSISTENCE IN CLINICAL PRACTICE AT A REGIONAL HOSPITAL	4CPS-087
	FOLIC ACID, FOLINIC ACID AND HEMATOTOXIC TREATMENTS: A REVIEW AT A UNIVERSITY HOSPITAL CENTRE	4CPS-088
	CLINICAL PHARMACIST EFFECTIVENESS IN HOSPITALISED PATIENTS: ANALYSIS OF THE INTERVENTION RECORD IN A SECONDARY ACUTE HOSPITAL	4CPS-089
	REAL-WORLD PERSISTENCE WITH FREMANEZUMAB VERSUS ERENUMAB AMONG MIGRAINE PATIENTS	4CPS-090
	REAL-LIFE PERSISTENCE, EFFECTIVENESS AND SAFETY OF FREMANEZUMAB IN PATIENTS WITH CHRONIC MIGRAINE	4CPS-091
	ANALYSIS OF ANTIBIOTICS CONSUMPTION AT AN ITALIAN CARDIOLOGY CENTRE: PHARMACOUSE PROFILE ACCORDING TO THE AWARE CLASSIFICATION	4CPS-092
	ANTIBIOTIC RESISTANCE IN THE HOSPITAL CONTEXT: RETROSPECTIVE ANALYSIS OF ANTIBIOGRAMS, RESISTANCE AND SENSITIVITY PROFILES AT AN ITALIAN HEART CENTER	4CPS-093
	RISK FACTORS FOR EMERGENCY DEPARTMENT RE-VISIT IN ELDERLY PATIENTS WITH GASTROINTESTINAL BLEEDING SECONDARY TO DIRECT ORAL ANTICOAGULANTS	4CPS-094
	EXPLORATORY ANALYSIS OF CARDIOVASCULAR EVENTS IN AN ASTHMATIC COHORT	4CPS-095
	USE OF COVID-19 ANTIVIRALS IN PATIENTS PREVIOUSLY TREATED WITH TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS: EXPERIENCE OF AN ITALIAN HOSPITAL	4CPS-096
	REAL-WORLD STUDY OF APALUTAMIDE TREATMENT IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN NINE HOSPITALS OF VALENCIAN COMMUNITY.	4CPS-097
	EFECTIVENESS AND SAFETY OF LONG-ACTING CABOTEGRAVIR/RILPIVIRINE IN REAL-LIFE POPULATION	4CPS-098
	CHIMERIC ANTIGEN RECEPTOR-T CELLS (CAR-T CELLS) AND ANTIBIOTICS : A NOT-SO-INNOCENT ASSOCIATION	4CPS-099
	THE UTILITY OF EARLY PHARMACEUTICAL VALIDATION OF SELECTED HIGH-RISK DRUGS IN A HOSPITAL EMERGENCY DEPARTMENT	4CPS-100
	MONITORING METABOLIC SYNDROME IN OLANZAPINE TREATED PATIENTS	4CPS-101
	AMIODARONE AND LITHIUM-INDUCED THYROID DYSFUNCTION: WHO INITIATES THE PRESCRIBING CASCADE?	4CPS-102
	ANALYSIS OF PNEUMONIA ASSOCIATED WITH MECHANICAL VENTILATION IN CRITICALLY ILL PATIENTS UNDERGOING SELECTIVE DIGESTIVE DECONTAMINATION.	4CPS-103
	COMORBIDITY PATTERNS IN THE OLDER HIV PATIENT	4CPS-104
	MEDICINES OPTIMISATION FOR PATIENTS IN A NURSING HOME	4CPS-105
	AUC-SURVIVAL REANALYSIS OF TROPICS-02 TRIAL WITH SACITUZUMAB GOVITECAN FOR METASTATIC LUMINAL BREAST CANCER.	4CPS-106
	ADHERENCE TO DAILY ORAL TREATMENT IN MULTIPLE SCLEROSIS	4CPS-107
	CLINICAL IMPACT OF PHARMACOKINETIC MONITORING OF INFLIXIMAB AND ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE	4CPS-108
	SEX-RELATED DIFFERENCES IN THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS TREATMENT	4CPS-109
	SYSTEMATIC REVIEW AND E-QUESTIONNAIRE ON THE SERVICE CHARACTERISTICS, OPERATIONS AND ACTIVITIES OF CENTRES FOR MEDICINES INFORMATION (CMI)	4CPS-110
	PHARMACEUTICAL INTERVENTIONS IN PATIENTS UNDER CHRONIC OPIOID TREATMENT ADMITTED TO TRAUMATOLOGY UNITS	4CPS-111
	ANTIMICROBIAL STEWARDSHIP PROGRAMME INTERVENTIONS IN INTENSIVE CARE UNIT	4CPS-112
	THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS	4CPS-113
	SUBLINGUAL ADMINISTRATION OF TACROLIMUS IN LIVER TRANSPLANT PATIENT WITH INTESTINAL MALABSORPTION: A CASE REPORT	4CPS-114
	CHRONIC MIGRAINE REVERSION AND SYMPTOMATIC MEDICATION REDUCTION WITH FREMANEZUMAB	4CPS-115
	REAL-WORLD EFFECTIVENESS AND COSTS OF USTEKINUMAB IN PATIENTS DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE	4CPS-116
	UPDATE OF STOPP/START CRITERIA IN 2023: WHAT ARE THE IMPACTS ON OUR PHARMACEUTICAL INTERVENTIONS?	4CPS-117
	MEDICATION ADHERENCE TO PSORIASIS TREATMENTS: A POPULATION-BASED STUDY	4CPS-118
	A REAL-LIFE STUDY OF PHARMACOKINETIC MONITORING: NEPHROTOXIC IMPACT OF AMINOGLYCOSIDES AND VANCOMYCIN	4CPS-119
	EFFICACY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY REAL-WORLD ANALYSIS AND COMPARISON WITH THE PIVOTAL STUDY (PS)	4CPS-120
	OPTIMISING ANTIDIABETIC TREATMENT FOR ELDERLY PATIENTS ACCORDING TO THEIR FUNCTIONAL STATUS	4CPS-121
	ANALYSIS OF THE USE AND EFFECTIVENESS OF FIDAXOMICIN IN CLOSTRIDIOIDES DIFFICILE INFECTION	4CPS-122
	SARGRAMOSTIM AND LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF CHRONIC VISCERAL LEISHMANIASIS IN HIV CO-INFECTED PATIENT: A CASE REPORT	4CPS-123
	MONITORING OF HIGH-COST ANTIBIOTIC’S PRESCRIPTIONS IN ORDER TO ENSURE PRESCRIPTIVE APPROPRIATENESS, PATIENT SAFETY AND CONTAINING EXPENDITURE	4CPS-124
	PHARMACEUTICAL CONSULTATIONS DEDICATED TO DIRECT ORAL ANTICOAGULANTS FOR CANCER PATIENTS: A SINGLE-CENTER PROSPECTIVE STUDY	4CPS-125
	ADHERENCE, PERSISTENCE, AND SWITCHING MEDICATION IN PATIENTS WITH MULTIPLE SCLEROSIS INITIATING ORAL DISEASE MODIFYING THERAPIES: A RETROSPECTIVE REAL-WORLD STUDY	4CPS-126
	PERSISTENCE OF BIOLOGICAL DISEASE-MODIFYING DRUGS AND PHOSPHODIESTERASE-4- INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITHIS	4CPS-127
	POTENTIAL DRUG-DRUG INTERACTIONS IN HYPERTENSIVE PATIENTS	4CPS-128
	EVALUATION OF THE BENEFIT OF CAROB FLOUR ON NINTEDANIB DIARRHEA IN THE TREATMENT OF DIFFUSE INTERSTITIAL LUNG DISEASE	4CPS-129
	RISK OF HYPOKALAEMIA IN HOSPITALIZED PATIENTS ASSOCIATED WITH THE COMBINATION OF DIURETICS	4CPS-130
	UTILIZATION AND SAFETY PROFILE OF UPADACITINIB IN A TERTIARY HOSPITAL	4CPS-131
	RIBOCICLIB IN METASTASIC BREAST CANCER TREATMENT: FRECUENCY AND ANALYSIS OF DIFFERENTS ADVERSE EFFECTS WHICH REQUIRED INTERVENTION	4CPS-132
	EFFECTIVENESS AND SAFETY OF ANTI IL-5 DRUGS BENRALIZUMAB AND MEPOLIZUMAB IN SEVERE UNCONTROLLED EOSINOPHILIC ASTHMA PATIENTS	4CPS-133
	REAL WORLD EVIDENCE OF CEFIDEROCOL IN CLINICAL PRACTICE	4CPS-134
	EVALUATION AND MANAGEMENT OF CONSTIPATION IN THE CRITICALLY ILL PATIENT	4CPS-135
	ANALYSIS OF THE SITUATION OF PHARMACEUTICAL CARE FOR PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES BEFORE AND AFTER THE COVID-19 PANDEMIC	4CPS-136
	CEFIDEROCOL: UTILIZATION PROFILE IN THE TREATMENT OF MULTIDRUG-RESISTANT BACTERIA, A RETROSPECTIVE OVERVIEW.	4CPS-137
	CEFIDEROCOL: EFFECTIVENESS AND MORTALITY OF MULTIDRUG-RESISTANT BACTERIA INFECTIONS, A RETROSPECTIVE OVERVIEW.	4CPS-138
	VORICONAZOLE SERUM CONCENTRATIONS MONITORING	4CPS-139
	EXPERIENCE OF USING PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN A TERTIARY HOSPITAL	4CPS-140
	REAL-LIFE IMPACT OF INCLUDING MONTELUKAST AS PREMEDICATION ON THE INCIDENCE OF INFUSION-RELATED REACTIONS TO ISATUXIMAB AND DESCRIPTION OF RISK FACTORS	4CPS-141
	COMMUNITY PHARMACY-BASED HBA1C SCREENING FOR EARLY DETECTION OF DIABETES AND PRE-DIABETES	4CPS-142
	A DESCRIPTION OF PHARMACISTS’ INTERVENTIONS TO OPTIMISE THE TREATMENT OF ADULTS WITH ORALLY AVAILABLE COVID-DRUG PAXLOVID®	4CPS-143
	BIOLOGICAL TREATMENTS IN THE PREVENTION OF MIGRAINE: RESTART AND DURATION OF THERAPEUTIC REST	4CPS-144
	COLLABORATIVE IMPLEMENTATION OF ‘WALANT’ (LOCAL ANESTHETIC) TECHNIQUE IN A HAND SURGERY WARD	4CPS-145
	ECONOMIC IMPACT ON MULTIPLE MYELOMA CLINICAL TRIALS IN THE PHARMACY SERVICE	4CPS-146
	OSIMERTINIB: A PROMISING TREATMENT FOR EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER	4CPS-147
	EAVLUATION OF DAILY DOSE MANUAL DRUG DISPENSING ACCURACY	4CPS-148
	CENTRAL VENOUS CATHETER-RELATED BLOODSTREAM INFECTIONS IN PATIENTS ON TOTAL PARENTERAL NUTRITION	4CPS-149
	PHARMACEUTICAL INTERVENTIONS IN OBESE PATIENTS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION	4CPS-150
	ANALYSIS OF ANTIBIOTIC TREATMENT IN PATIENTS WITH VENTILATOR-ASSOCIATED PNEUMONIA	4CPS-151
	THE INCLUSION OF TRAMADOL FOR PARENTERAL USE IN THE NARCOTIC TABLE OF PHARMACOPOEIA: ANALYSIS OF EFFECTS AND CONSUMPTION IN A GENERAL HOSPITAL SETTING	4CPS-152
	ECONOMIC BENEFIT ANALYSIS ON LUNG CANCER CLINICAL TRIALS: MEDICATION AND MEDICAL TESTS	4CPS-153
	THERAPEUTIC DRUG MONITORING OF AMIKACIN IN NEONATES: ABOUT A NEW PROTOCOL	4CPS-154
	PERCEPTION OF HOSPITAL PHARMACIES ABOUT TELEPHARMACY IN THE PROVISION OF HEALTHCARE FOR PEOPLE LIVING WITH HIV	4CPS-155
	ANALYSIS OF THE PRESCRIPTION PATTERN AND DAYS OF HOSPITALIZATION AVOIDED BY OUTPATIENT INTRAVENOUS ANTIBIOTIC THERAPY AND THE SAFETY OF THIS PRACTICE	4CPS-156
	PERSPECTIVES OF PATIENTS AND MEDICAL PROVIDERS ON MULTIDISCIPLINARY MEDICATION RECONCILIATIONS SERVICE IN ADULT PATIENTS UNDERGOING THORACIC AND CARDIOVASCULAR SURGERY (MERITS STUDY)	4CPS-157
	RELAPSED/REFRACTORY MULTIPLE MYELOMA AND NEW THERAPEUTIC OPTIONS: EXPERIENCE IN A PHASE I CLINICAL TRIALS UNIT	4CPS-158
	ANALYSIS OF THE INTERVENTIONS CARRIED OUT IN THE GERIATRIC SERVICE IN COLLABORATION WITH THE INTERNAL MEDICINE AND MICROBIOLOGY SERVICES	4CPS-159
	LONG-TERM EFFECTIVENESS AND SAFETY RESULTS OF GALCANEZUMAB IN REAL-WORLD DATA IN MIGRAINE PROPHYLAXIS	4CPS-160
	VANCOMYCIN PHARMACOKINETIC MONITORING IN CRITICALLY ILL NEONATAL PATIENTS	4CPS-161
	“TO ERR IS HUMAN“: PRESENTING CASES OF MEDICATION ERRORS FROM REAL CLINICAL PRACTICE	4CPS-162
	EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN HOSPITALISED PATIENTS WITH HYPERKALAEMIA	4CPS-163
	ANALYSIS OF USTEKINUMAB INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE ACCORDING TO LINE OF TREATMENT	4CPS-164
	DETERMINATION OF PREDICTIVE FACTORS FOR IMMUNE-RELATED TOXICITY IN LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPY	4CPS-165
	COMPREHENSIVE ASSESSMENT OF PHARMACOTHERAPY IN THE COMPLEX CHRONIC PATIENT: COLLABORATION BETWEEN DIFFERENT LEVELS OF CARE	4CPS-166
	USE OF STANDARD- AND HIGH-DOSE LIPOSOMAL AMPHOTERICIN B AND ITS RELATIONSHIP WITH HYPOMAGNESEMIA	4CPS-167
	EFFECTIVENESS, SAFETY AND ADHERENCE TO EVOLOCUMAB IN REAL CLINICAL PRACTICE	4CPS-168
	EVALUATION OF ANTICHOLINERGIC DRUG PRESCRIPTION USING A CLINICAL DECISION SUPPORT SYSTEM: A PROSPECTIVE STUDY IN A GERIATRIC REHABILITATION CENTER	4CPS-169
	CLINICAL PHARMACY PRIORITISATION ALGORITHM FOR PATIENTS IN PSYCHIATRIC LONG-TERM CARE: A PILOT STUDY	4CPS-170
	FIXED-DOSE VERSUS WEIGHT-BASED DOSING REGIMEN OF PEMBROLIZUMAB	4CPS-171
	IMPROVING POST-OPERATIVE ANALGESIA AND ASSOCIATED PRESCRIBING IN THE ORTHOPAEDIC SETTING	4CPS-172
	PRESCRIPTION OF PSYCHOTROPIC DRUGS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION ON INTEGRASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY	4CPS-173
	NASAL ESKETAMINE USE FOR MAYOR DEPRESSIVE DISORDER, FROM A THIRD LEVEL HOSPITAL TO PERIPHERAL MENTAL CENTERS	4CPS-174
	EFFECTIVENESS OF IMMUNOTHERAPY AS A FUNCTION OF AGE: METHA-ANALYSIS OF THE APPROVED COMBINATIONS IN FIRST LINE METASTASIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITHOUT MUTATIONS.	4CPS-175
	USE AND PERSISTENCE OF GUSELKUMAB IN TREATMENT FOR RHEUMATIC AND DERMATOLOGICAL DISEASE	4CPS-176
	LONG-ACTING INTRAMUSCULAR ANTIRETROVIRALS: WHAT REAL-WORLD DATA DO WE HAVE?	4CPS-177
	EFFECT OF PCSK9 INHIBITORS ON HYPERCHOLESTEROLEMIA	4CPS-178
	REAL-LIFE ANALYSIS OF THE DEVELOPMENT OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THERAPEUTIC APPROACH.	4CPS-179
	SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: COMPARISON OF OUR DATA TO THE ASCENT TRIAL AFTER TWO YEARS OF EXPERIENCE	4CPS-180
	ELECTRONIC PRESCRIBING IN THE NEONATAL INTENSIVE CARE UNIT: ANALYSIS OF PRESCRIBING ERRORS AND RISK FACTORS	4CPS-181
	DESCRIPTION OF A CLINICAL PHARMACIST INTERVENTION FOCUSED ON MANAGEMENT OF A CHRONIC DISEASE AT HOSPITAL: THE EXAMPLE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).	4CPS-182
	PHARMACIST-LED OPT-OUT CESSATION TREATMENT PROTOCOL FOR COMBUSTIBLE TOBACCO SMOKING	4CPS-183
	THERAPIES IN ENDOMETRIAL CANCER WITH DNA MISMATCH REPAIR DEFICIENT OR MICROSATELLITE INSTABILITY: A SYSTEMATIC REVIEW	4CPS-184
	ANALYSIS OF THE USE OF MEDICATION NOT INCLUDED IN THE PHARMACOTHERAPEUTIC GUIDE OF A TERTIARY HOSPITAL	4CPS-185
	IMPLEMENTATION OF A PATIENT STRATIFICATION MODEL IN OUTPATIENT PHARMACY FOR IMMUNE-MEDIATED DERMATOLOGICAL DISEASES	4CPS-186
	DEVELOPMENT OF A POPULATION PHARMACOKINETIC MODEL OF CYCLOSPORINE	4CPS-187
	IMPLEMENTATION OF THIOPURINE PHARMACOGENETICS TO IMPROVE PEDIATRIC SAFETY AT A TERTIARY HOSPITAL	4CPS-188
	LOCAL EXPERIENCE ON THE USE OF CANNABIDIOL FOR THE TREATMENT OF REFRACTORY EPILEPSY. SAFETY AND EFFICACY ON A 10 PATIENT’S COHORT	4CPS-189
	DEVELOPMENT OF TRANSMURAL PHARMACEUTICAL CARE IN A GENERAL HOSPITAL	4CPS-190
	PRE-RADIOIODINE THERAPY SURGICAL MODALITIES: COMPARION OF POST-OPERATIVE THYROGLOBULIN LEVELS IN PATIENTS UNDERGOING 1- OR 2-STEP THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER	4CPS-191
	ASTHMA AND RISK OF CARDIOVASCULAR EVENTS: A RETROSPECTIVE STUDY	4CPS-192
	EFFECTIVENESS AND SAFETY OF INTRAVENOUS USTEKINUMAB INTENSIFICATION IN CROHN’S DISEASE WITH LOSS OF RESPONSE OR PARTIAL RESPONSE TO SUBCUTANEOUS THERAPY	4CPS-193
	EVOLUTION OF HOSPITAL CLINICAL PHARMACY SERVICES IN FINLAND DURING YEARS 2017-2022: A FOLLOW-UP SURVEY	4CPS-194
	CHARACTERIZATION OF INJECTABLE FORMULATIONS AND OPTIMIZATION OF THEIR DELIVERY BY ENTERAL TUBE: A PHYSICOCHEMICAL AND PHYSIOLOGICAL APPROACH	4CPS-195
	ASSESSMENT OF ORAL DRUG THERAPY REGARDING ABSORPTION DISORDERS IN PATIENTS WITH INTESTINAL OSTOMIES – AN OBSERVATIONAL STUDY	4CPS-196
	THE KTIA-SCORAC STUDY : SECURING THE MEDICATION MANAGEMENT OF ELDERLY PATIENTS BY THE SYSTEMATIC EVALUATION OF ANTICHOLINERGIC LOAD SCORES VIA A CLINICAL DECISION SUPPORT SYSTEM	4CPS-197
	EVALUATION OF PROA TEAM INTERVENTION ACCEPTANCE RATES THROUGH AN AUTOMATED MEASUREMENT SYSTEM	4CPS-198
	COMPARATIVE EVALUATION OF ENZYME-LINKED IMMUNOSORBENT ASSAY VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS	4CPS-199
	TRIPLE THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS BASED ON A PHARMACOLOGICAL TREATMENT ALGORITHM	4CPS-200
	CLINICAL EXPERIENCE OF TYROSINE-KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA	4CPS-201
	EVALUATION OF THE EXCHANGE OF ANTICGRP MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CHRONIC REFRACTORY MIGRAINE	4CPS-202
	DEVELOPMENT AND VALIDATION OF A DATA COLLECTION TOOL TO EVALUATE PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT	4CPS-203
	MONITORING OF LINEZOLID IN HEMODIALYSIS: A CLINICAL CASE	4CPS-204
	RESULTS OF ANTIBIOTIC PROPHYLAXIS IN ACUTE BRONCHOASPIRATION PNEUMONITIS	4CPS-205
	PRE-EXPOSURE PROPHYLAXIS, ARE WE DOING IT RIGHT?	4CPS-206
	EVALUATION OF PROSTATIC SPECIFIC ANTIGEN DEPLETION WITH ABIRATERONE AS A PRONOSTATIVE FACTOR FOR SURVIVAL IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER	4CPS-207
	ANALYSIS OF THE IMPLEMENTATION OF A MULTIDISCIPLINARY PHARMACEUTICAL CARE PROJECT FOR GERIATRIC HEMATO-ONCOLOGY PATIENTS	4CPS-208
	COMPARISON OF TWO PHARMACOKINETIC/PHARMACODYNAMIC INDICES IN CRITICALLY ILL PATIENTS TREATED WITH AMIKACIN	4CPS-209
	HOME INFUSION CHEMOTHERAPY TREATMENT FOR PATIENTS WITH MALIGNANT HAEMATOLOGICAL DISORDERS	4CPS-210
	TITLE: ANALYSIS OF THE PRESCRIPTION OF VITAMIN D SUPPLEMENTS IN A SOCIAL HEALTH CENTER.	4CPS-211
	MANAGEMENT OF POST CAR-T NEUROTOXICITY USING ANAKINRA. A CASE REPORT	4CPS-212
	RESULTS OF ANTIBIOTIC TREATMENT OF AORTIC ENDOPROSTHESIS INFECTIONS IN PATIENTS NOT CANDIDATES FOR SURGERY	4CPS-213
	MONITORING OF TACROLIMUS IN A KIDNEY TRANSPLANTED COHORT	4CPS-214
	ADJUSTMENT OF ANTIBIOTICS THROUGH THE HEMOFILTER: A CASE REPORT	4CPS-215
	EFFICACY AND SAFETY ANALYSIS OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS: REAL-LIFE DATA.	4CPS-216
	A COMPARATIVE EVALUATION OF THE LONG-TERM EFFECTIVENESS OF GUSELKUMAB AND RISANKIZUMAB IN THE CLINICAL MANAGEMENT OF PLAQUE PSORIASIS.	4CPS-217
	OPIOID PRESCRIBING FOR ACUTE NON-CANCER PAIN, POST-OPERATIVE PAIN AND POST-PROCEDURE PAIN BY SURGICAL TEAMS AT A TERTIARY HOSPITAL: 1-DAY AUDIT	4CPS-218
	BEYOND THE EXPECTED: THE ENHANCED DETECTION OF DRUG RELATED PROBLEMS, THE MOST OF A PHARMACEUTICAL DECISION SUPPORT SYSTEM	4CPS-219
	EVALUATION OF THE IMPLEMENTATION OF A PRE-EXPOSURE PROPHYLAXIS PROGRAM. 2 YEARS EXPERIENCE IN OUR REGION	4CPS-220
	EVALUATION OF THE RELEVANCE OF STATINS PRESCRIPTION IN THE ELDERLY : TOWARDS A DEPRESCRIPTION ?	4CPS-221
	THE REAL LIFE OF BENZODIAZEPINES IN GERIATRIC DEPARTMENT : CAN THE PHARMACIST HAVE AN IMPACT ?	4CPS-222
	A STUDY ON THE PERCEPTION OF ELDERLY PATIENTS ON THE EXPIRATION DATE AND STORAGE OF PRESCRIBED MEDICATION: A QUESTIONNAIRE STUDY	4CPS-223
	MEDICATION RECONCILIATION IN A SURGERY DEPARTMENT: 6-MONTHS EXPERIENCE	4CPS-224
	DEFINING INTERNATIONAL CRITICAL CARE PHARMACIST ASPIRATIONS TO THE MANAGEMENT OF SEPSIS	4CPS-225
	PHARMACEUTICAL INTERVENTION ON THE ADEQUACY OF THE INDICATION OF SEMAGLUTIDE IN DIABETES MELLITUS 2	4CPS-226
	PHARMACEUTICAL REVIEW AND PHARMACEUTICAL INTERVENTION IN A NURSING HOME TO ENHANCE THE MEDICATION MANAGEMENT OF RESIDENTS.	4CPS-227
	IMPACT AND ACCEPTANCE OF PHARMACEUTICAL INTERVENTIONS FOR EARLY MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT	4CPS-228
	SUSTAINABILITY: A PERSON-CENTRED, WHOLE SYSTEMS APPROACH TO MEDICINES OPTIMISATION	4CPS-229
	CLINICAL PHARMACOGENOMICS FOR A SAFER USE OF FLUOROPYRIMIDINES	4CPS-230

Section 5: Patient Safety and Quality Assurance

PDF Document	Poster Title	Poster Number
	INCIDENCE OF HEPATITIS B VIRUS REACTIVATION IN PSORIASIS PATIENTS TREATED WITH CYTOKINE INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS	5PSQ-001
	PRESCRIBING TREND OFFLUOROQUINOLONES FOLLOWING LATEST EMA RECOMMENDATIONS	5PSQ-002
	IMPROVING MEDICINES MANAGEMENT OF INPATIENT PARKINSON’S DISEASE PATIENTS BY MAKING PHARMACY INTERVENTIONS	5PSQ-003
	COMPARISON BETWEEN BEERS 2019 CRITERIA AND THE EURO-FORTA 2018 LIST IN THE IDENTIFICATION OF POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY PATIENTS IN THE PRIMARY HEALTHCARE CONTEXT	5PSQ-004
	UTILITY OF THE THERAPEUTIC COMPLEXITY INDEX ADAPTED TO CRITICALLY ILL PATIENTS AS A METHOD OF STRATIFICATION FOR PHARMACEUTICAL CARE	5PSQ-005
	FREQUENCY OF CREATININE TESTING AND ACUTE KIDNEY INJURY IDENTIFICATION AND STAGING.	5PSQ-006
	A REVIEW ON MEDICATION RECONCILIATION IN THE PERIOPERATIVE PERIOD: VARIABLES THAT LEAD TO MEDICATION ERRORS.	5PSQ-007
	IMMUNE-MEDIATED HEPATITIS SECONDARY TO TREATMENT WITH PEMBROLIZUMAB. A CASE REPORT.	5PSQ-008
	OFF-LABEL USE OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS ACUTE LUPUS PNEUMONITIS: A CASE REPORT	5PSQ-009
	NATIONAL STANDARDISATION OF PRETERM PARENTERAL NUTRITION IN NEONATAL UNITS	5PSQ-010
	TOXICITY OF IMMUNOTHERAPY TREATMENT IN CLINICAL PRACTICE	5PSQ-011
	TOOLS OFFERED BY REGENERATIVE MEDICINE FOR THE TREATMENT OF OSTEOARTHRITIS – PLATELET RICH PLASMA (PRP).	5PSQ-012
	NEW METHOD FOR ASSESSMENT OF ENVIRONMENTAL VIRAL CONTAMINATION OF LIQUIDS PREPARED IN CLOSED-SYSTEM DRUG TRANSFER DEVICES	5PSQ-013
	ELECTRONIC COMMUNICATION OF THE DISCONTINUATION OF HOME TREATMENT PRESCRIBED TO PATIENTS IN A TERTIARY LEVEL HOSPITAL.	5PSQ-014
	ANALYSIS OF THE OCCURRENCE OF ATRIAL FIBRILLATION WITH THE ADMINISTRATION OF IBRUTINIB: SHOULD WE BE CAREFUL WITH THIS DRUG?	5PSQ-015
	ASSESSMENT OF THE ACCREDITATION AND CONTINUOUS EDUCATION TESTS FOR PHARMACY TECHNICIANS WITHIN A CYTOTOXIC RECONSTITUTION UNIT	5PSQ-016
	PHARMACEUTICAL INTERVENTIONS IN ORAL AND SUBCUTANEOUS MTX PRESCRIBING ERRORS	5PSQ-017
	ANALYSIS OF ERRORS IN THE MANUAL PREPARATION OF STERILE DRUGS FROM STOCK.	5PSQ-018
	VALIDATION PRIOR TO THE DISPENSING OF MEDICINES AS A TOOL TO IMPROVE THE QUALITY OF THE PRESCRIPTION	5PSQ-019
	EVALUATION OF THE EFFICACY AND SAFETY OF EPCORITAMAB-BYSP IN PATIENTS WITH FOLLICULAR B LYMPHOMA: A CASE REPORT.	5PSQ-020
	EVALUATION OF THE PREVALENCE OF MULTI-RESISTANT BACTERIA IN THE INTENSIVE CARE UNIT AFTER SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT.	5PSQ-021
	DRUG-INDUCED APLASTIC ANAEMIA: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)	5PSQ-022
	SAFETY AND TOLERABILITY OF VORICONAZOLE TREATMENT: A RETROSPECTIVE OBSERVATIONAL STUDY	5PSQ-023
	ENHANCING SAFETY AND EFFICIENCY IN CHEMOTHERAPY PREPARATION AND ADMINISTRATION IN A SMALL ONCOLOGY HOSPITAL	5PSQ-024
	AUDIT ON THE CORRECT USE OF MEDICAL DEVICES FOR URINARY CATHETERISATION	5PSQ-025
	THE POTENTIAL OF PHARMACOVIGILANCE DATABASES TO ASSESS TOXICOLOGICAL RISK OF DIETARY SUPPLEMENTS AND OTHER UNSUPERVISED HEALTH PRODUCTS USED BY PATIENTS	5PSQ-026
	VARIABILITY IN VANCOMYCIN PLASMA CONCENTRATION IN NEUTROPENIC PATIENTS	5PSQ-027
	CASE REPORT: ANTITUMOR ACTIVITY AND TOXICITIES OF ENTRECTINIB IN A PATIENT WITH A PRIMARY CENTRAL NEUROCYTOMA	5PSQ-028
	THE OVERRIDING OF DRUG SAFETY ALERTS FIRED BY THE CLINICAL DECISION SUPPORT TOOL: EVALUATION OF APPROPRIATE RESPONSES AND ALERT FATIGUE SOLUTIONS	5PSQ-029
	CONCORDANCE OF MEDICATION PRESCRIPTION RECORDS IN THE HOSPITALISED SURGICAL PATIENT	5PSQ-030
	“ASSESSING HEALTHCARE PROFESSIONALS “VIEWS ON DEPRESCRIPTION	5PSQ-031
	USE OF THE “PRECAUTIONARY ANNULMENTS” TOOL BY A HOSPITAL PHARMACY SERVICE	5PSQ-032
	TEMPORAL TRENDS OF ATYPICAL DRUG ACCESS AT AN ACADEMIC ONCOLOGY UNIT: THE VERONA UNIVERSITY HOSPITAL EXPERIENCE	5PSQ-033
	COMPARISON OF TOXICITY IN CLINICAL PRACTICE OF ANTI-PD-1/PD-L1 ANTIBODIES IN MONOTHERAPY IN NON-SMALL CELL LUNG CANCER	5PSQ-034
	SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: A MULTICENTER EFFECTIVENESS AND SAFETY STUDY	5PSQ-035
	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON ANTIMICROBIAL PRESCRIPTIONS IN THE POSTOPERATIVE RESUSCITATION UNIT	5PSQ-036
	PERIPHERAL BLOOD BIOMARKERS DYNAMICS PREDICT CLINICAL RESPONSE TO PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL CELL LUNG CANCER	5PSQ-037
	REAL-WORLD SAFETY OF IBRUTINIB IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA	5PSQ-038
	IMPACT OF TAILORED SCREENING INTERVALS ON THE BURDEN OF DRUG-DRUG INTERACTION ALERTS: AN INTERRUPTED TIME SERIES ANALYSIS	5PSQ-039
	VOLUNTARY MEDICATION ERRORS REPORTING SYSTEM IN AN ORTHOPEDIC SURGERY AND TRAUMATOLOGY UNIT	5PSQ-040
	IMPACT OF INTRODUCING PREFILLED ATROPINE SYRINGES IN OCULAR SURGERY: PROACTIVE ASSESSMENT OF DRUG COSTS AND MEDICATION SAFETY	5PSQ-041
	FOCUS ON MEDICATION ERRORS ON HIGH-RISK MEDICATIONS IN A HOSPITAL’S ELECTRONIC INCIDENT REPORTING SYSTEM	5PSQ-042
	DESCRIPTIVE STUDY OF MARKETED MEDICINES CONTAINING ASPARTAME	5PSQ-043
	SAFETY OF PEMBROLIZUMAB +/- CHEMOTHERAPY IN FIRST-LINE METASTATIC NON-SMALL-CELL LUNG CARCINOMA IN REAL-WORLD PRACTICE	5PSQ-044
	ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS WITH DEMENTIA AND IN TREATMENT WITH HIGH ANTICHOLINERGIC ACTIVITY DRUGS	5PSQ-045
	SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE INDUCED BY ALPRAZOLAM: A CASE REPORT	5PSQ-046
	THE PERCEIVED IMPACT ON PATIENT SAFETY AND QUALITY OF CARE OF PHARMACEUTICAL TECHNICAL ASSISTANTS ON NURSING WARDS: A QUALITATIVE STUDY	5PSQ-047
	COST-SAVING IMPACT OF USING NUSINERSEN BY CLINICAL TRIALS FOR SPINAL MUSCULAR ATROPHY	5PSQ-048
	MEDICATION PRESCRIBING ERRORS PROSPECTIVE OBSERVATIONAL STUDY IN AN INTENSIVE CARE UNIT	5PSQ-049
	IT IS POSSIBLE TO IMPROVE THE HIPOPOTASEMIC MANAGMENT IN THE HOSPITAL?	5PSQ-050
	EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN OLDER PATIENTS AT NURSING HOME WITH COVID-19.	5PSQ-051
	ANALYSIS OF POTENTIAL PROGNOSTIC FACTORS OF EFFICACY IN TISAGENLECLEUCEL TREATMENT IN A COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	5PSQ-052
	EFFECTIVENESS AND SAFETY OF GALCANEZUMAB. REAL-LIFE RESULTS.	5PSQ-053
	EVALUATION OF AN APPLICATION TO HELP FOR THE ADEQUACY OF THE DOSAGE OF ANTIBIOTICS IN RENAL FAILURE	5PSQ-054
	EFFICACY AND SAFETY OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS TREATMENT	5PSQ-055
	VACCINATION COVERAGE AGAINST PENUMOCOCCUS FOR PEOPLE LIVING WITH HIV BEFORE AND AFTER THE COVI-19 PANDEMIC	5PSQ-056
	ANTICHOLINERGIC BURDEN ASSESSMENT IN INSTITUTIONALIZED PATIENTS	5PSQ-057
	EFFICACY EVALUATION OF ANTI-PCSK9 DRUGS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA.	5PSQ-058
	STUDY OF THE USE OF CEFTAZIDIME/AVIBACTAM IN A FIRST LEVEL HOSPITAL	5PSQ-059
	REAL-LIFE DATA ON THE EFFECTIVENESS AND SAFETY OF CABOTEGRAVIR/RILPIVIRINE IN A THIRD-LEVEL HOSPITAL	5PSQ-060
	CURRENT PRACTICE OF PEDIATRIC OFF-LABEL PRESCRIPTIONS IN A PEDIATRIC HOSPITAL	5PSQ-061
	SAFETY EVALUATION OF PEMBROLIZUMAB IN MONOTHERAPY	5PSQ-062
	ADJUVANTE ANALGESICS INTERACTIONS: HOW TO MANAGE PAIN IN PATIENTS RECEIVING ORAL THERAPY FOR BREAST CANCER TREATMENT	5PSQ-063
	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON DIRECT ACTING ORAL ANTICOAGULANTS IN A TERTIARY CARE HOSPITAL.	5PSQ-064
	INTESTINAL PERFORATION AFTER CRS AND ICANS IN A CAR-T TREATED PATIENT: A CLINICAL CASE REPORT.	5PSQ-065
	SURVIVAL ANALYSIS OF REGORAFENIB IN PATIENTS WITH COLORECTAL CANCER. FIRST RESULTS OF REGORAFENIB USE IN REAL CLINICAL PRACTICE	5PSQ-066
	DRUG UTILIZATION PROFILES OF ADVANCED THERAPY MEDICINAL PRODUCTS: A REAL WORLD EVIDENCE STUDY	5PSQ-067
	THE HOSPITAL PHARMACIST’S INTERVENTIONS IN THE POST-MARKETING PHARMACOVIGILANCE OF ANTI-ASTHMATIC BIOLOGICS: A REAL LIFE ANALYSIS	5PSQ-068
	COMPARISON OF RENAL GLOMERULAR FILTRATION ESTIMATION FORMULAS IN VANCOMYCIN PHARMACOKINETIC MONITORING	5PSQ-069
	DUPILUMAB IS A MONOCLONAL ANTIBODY USED FOR THE TREATMENT OF ATOPIC DERMATITIS. THIS STUDY EVALUATES THE EFFECTIVENESS AND PERSISTENCE. DUPILUMAB PRESENTS GOOD EFFECTIVENESS AND PERSISTENCE.	5PSQ-070
	MULTIDISCIPLINARY MANAGEMENT OF DRESS SYNDROME: A CASE REPORT	5PSQ-071
	TREATMENT WITH GALCANEZUMAB IN REAL WORLD DATA: SAFETY.	5PSQ-072
	RISK SCORE FOR DRUG DISCREPANCY AND ADHERENCE IN CLINICAL TRIAL PATIENTS	5PSQ-073
	PHARMACEUTICAL INTERVENTIONS IN PAIN MANAGEMENT	5PSQ-074
	ADHERENCE TO LOCAL ANTIBIOTIC PRESCRIBING GUIDELINES WITHIN 48 HOURS OF INPATIENT ADMISSION	5PSQ-075
	EFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY VS NIVOLUMAB PLUS IPILIMUMAB IN RENAL CELL CARCINOMA IN CLINICAL PRACTICE	5PSQ-076
	ADEQUATE NUTRITIONAL THERAPY IN CRITICAL PATIENTS WITH CORONAVIRUS DISEASE (COVID-19)	5PSQ-077
	HYPOPHOSPHATEMIA AFTER FERRIC CARBOXYMALTOSE ADMINISTRATION IN A COHORT OF ELDERLY PATIENTS WITH HIP FRACTURE	5PSQ-078
	PHARMACEUTICAL INTERVENTIONS IN A HEALTH MANAGEMENT AREA	5PSQ-079
	CLINICAL INTERVENTIONS IN PATIENTS UNDERGOING ANTIPARKINSONIAN TREATMENT: THE IMPORTANCE OF CORRECT RECONCILIATION	5PSQ-080
	SATISFACTION OF PHYSICIANS AND HOSPITAL PHARMACISTS OF A HYPERSENSITIVITY DOCUMENTATION TOOL WITH DE-LABELING FEATURE IN CLINICAL PRACTICE	5PSQ-081
	THIRD-GENERATION HOSPITAL-EXCLUSIVE CEPHALOSPORINS: DIFFERENT SAFETY PROFILES?	5PSQ-082
	MARIBAVIR-INDUCED TOXIC EPIDERMAL NECROLYSIS IN A LIVER TRANSPLANT PATIENT: A CASE REPORT.	5PSQ-083
	EROSIVE BALANITIS AS A POSSIBLE ADVERSE EFFECT TO TREATMENT WITH TOFACITINIB. A CASE REPORT.	5PSQ-084
	SAFETY ASSESSMENT OF JANUS KINASE INHIBITORS IN CLINICAL PRACTICE	5PSQ-085
	ADMINISTRATION OF TYROSINE KINASE INHIBITOR DRUGS IN PATIENTS WITH ENTERAL FEEDING TUBES	5PSQ-086
	ANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS	5PSQ-087
	ADHERENCE TO ANTIRETROVIRAL THERAPY IN VIH PATIENTS	5PSQ-088
	OUTCOME OF MOLNUPIRAVIR TREATMENT IN RENAL TRANSPLANT PATIENTS WITH COVID-19	5PSQ-089
	CAPSAICIN 8% PATCH IN TREATMENT OF PERIPHERAL NEUROPATHIC PAIN	5PSQ-090
	SUITABILITY OF TERIPARATIDE AND LEVEL OF ACCEPTANCE OF PHARMACOTHERAPEUTIC RECOMMENDATIONS IN AN AREA OF HEALTH MANAGEMENT	5PSQ-091
	ALTERED PHARMACOKINETICS PARAMETERS OF VANCOMYCIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY WITH FEBRILE NEUTROPENIA, A BAYESIAN SOFTWARE ESTIMATION	5PSQ-092
	DOES EXPOSURE TO ANTIBIOTICS PRIOR TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AFFECT THEIR EFFECTIVENESS?	5PSQ-093
	INCIDENCE OF HYPERSENSITIVITY REACTIONS IN PACLITAXEL INFUSIONS FOLLOWING THE DISCONTINUATION OF RANITIDINE.	5PSQ-094
	HOSPITAL PHARMACISTS ENGAGEMENT IN PHARMACOVIGILANCE PRACTICES DURING COVID-19 IN THE NORTH MACEDONIA	5PSQ-095
	DESCRIPTION OF INMMUNOGLOBULIN REPLACEMENT THERAPY IN MULTIPLE MYELOMA PATIENTS WITH ANTI-BCMA CART	5PSQ-096
	AN APPROACH TO THE USE OF MACHINE LEARNING TOOLS FOR THE PREDICTION OF ADVERSE EVENTS IN CANCER PATIENTS ON IMMUNOTHERAPY	5PSQ-097
	PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: OPTIMIZATION OF ACCESS TO THERAPY IN ACCORDANCE WITH EUROPEAN GUIDELINES	5PSQ-098
	DRUG-RELATED PROBLEMS ASSOCIATED WITH THE TREATMENT OF POLYCYSTIC OVARY SYNDROME	5PSQ-099
	SURVEY OF PATIENT INVOLVEMENT IN ADVERSE DRUG REACTION MONITORING: THEIR INFORMATION SOURCES AND NEEDS	5PSQ-100
	MEDICAL DEVICES INCIDENT REPORTS: AN ITALIAN EXPERIENCE	5PSQ-101
	ANALYSIS OF REPEATED EMERGENCY DEPARTMENT VISITS AND THEIR RELATIONSHIP TO MEDICATION	5PSQ-102
	VANCOMYCIN-INDUCED RENAL TOXICITY THROUGH THERAPEUTIC DRUG MONITORING IN DAILY PRACTICE	5PSQ-103
	REAL WORLD EVIDENCE: IS IBRUTINIB AS SAFE AS EVIDENCE TELLS?	5PSQ-104
	PATTERNS OF USE AND APPROPRIATENESS OF ANTICOAGULATION IN ATRIAL FIBRILLATION: AN OBSERVATIONAL STUDY AMONG GERIATRIC INPATIENTS	5PSQ-105
	FALL-INCREASING RISK DRUGS (FRIDS) AND FALL-RELATED FRACTURES	5PSQ-106
	COMPLIANCE OF FLUOROQUINOLONES PRESCRIPTIONS : A HOSPITAL ACQUIRED RESISTANCE ?	5PSQ-107
	EFFICACY AND SAFETY OF INFLIXIMAB IN NF-KB ESSENTIAL MODULATOR DELETED EXON 5 AUTO-INFLAMMATORY SYNDROME: A CASE REPORT	5PSQ-108
	HAEMOASSIST: A DIGITAL BRIDGE BETWEEN HAEMOPHILIA PATIENTS AND PHARMACISTS	5PSQ-109
	DESENSITIZATION TO MONOCLONAL ANTIBODIES IN ONCOHEMATOLOGICAL PATIENTS	5PSQ-110
	SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AFTER HEART TRANSPLANTATION	5PSQ-111
	A SURVEY OF HOME STORAGE TEMPERATURE OF IN-USE INSULINS AND ANALYSIS OF THEIR STABILITIES UNDER THE SIMULATED HIGHEST HOME TEMPERATURE	5PSQ-112
	ROOT CAUSE ANALYSIS: STATEGY FOR A SUSTAINABLE ANTIBLASTIC THERAPY MANAGEMENT SYSTEM	5PSQ-113
	HEAD AND NECK ERYTHEMA ASSOCIATED WITH THE USE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS	5PSQ-114
	EVALUATION OF HYPOTHYROIDISM ASSOCIATED WITH APALUTAMIDE AND ENZALUTAMIDE TREATMENT IN METASTATIC PROSTATE CANCER USING THE EUROPEAN ADVERSE EFFECT DATABASE (EUDRAVIGILANCE)	5PSQ-115
	REAL-WORLD PERSISTENCE WITH GUSELKUMAB AMONG ADULTS WITH PSORIATIC ARTHRITIS	5PSQ-116
	TRACEABILITY OF IMPLANTABLE MEDICAL DEVICES / PATIENT INFORMATION: WHERE DO WE STAND?	5PSQ-117
	NON-ACTIVE PRESCRIPTIONS IN AMBULATORY PATIENTS: ANALYSIS AND EFFECT IN CONSULTATION WAITING TIME	5PSQ-118
	REVIEW OF REAL-WORLD MANAGEMENT OF NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS: A DOUBLE-EDGED WEAPON	5PSQ-119
	PEMBROLIZUMAB IMMUNE-MEDIATED TOXICITY	5PSQ-120
	A REVIEW OF THE EXPOSURE TO POTENTIALLY HARMFUL EXCIPIENTS THROUGH ORAL LIQUID FORMS IN PEDIATRIC INPATIENTS IN FRANCE	5PSQ-121
	SEQUENTIAL CHANGE OF DOSING INTERVAL OF PALIPERIDONE PALMITATE BASED ON PLASMA CONCENTRATION MONITORING	5PSQ-122
	SIMUALTION OF A DISCHARGE CONTROL: AN EFFECTIVE TOOL FOR QUALIFYING STAFF	5PSQ-123
	THE TREATMENT OF PRESSURE ULCERS WITH BACTERIA BINDING MEDICATION AS A VALID THERAPEUTIC OPPORTUNITY	5PSQ-124
	ANALYSIS OF INTRODUCING PROBIOTICS FOR THE PREVENTION OF NECROTIZING ENTEROCOLITIS IN PREMATURE NEONATES IN A NEONATAL UNIT	5PSQ-125
	THE ANALYSIS OF INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN HOSPITALIZED SENIORS	5PSQ-126
	MEDICATION-RELATED FALLS IN A NURSING HOME: IDENTIFICATION AND HOSPITAL PHARMACY INTERVENTIONS	5PSQ-127
	COST-EFFECTIVENESS OF PHARMACEUTICAL PREOPERATIVE CONSULTATIONS: A FIVE-YEAR ANALYSIS	5PSQ-128

Section 6: Education and Research

PDF Document	Poster Title	Poster Number
	HEALTHCARE RESOURCE UTILIZATION AND COSTS OF INTRAVITREAL RANIBIZUMAB OR AFLIBERCEPT VS. DEXAMETHASONE FOR DIABETIC MACULAR EDEMA IN TAIWAN	6ER-001
	POSITIVE PREDICTIVE VALUES OF ANAPHYLAXIS DIAGNOSIS IN CLAIMS DATA: A MULTI-INSTITUTIONAL STUDY IN TAIWAN	6ER-002
	ASSESSMENT OF OVERALL SURVIVAL AND SAFETY IN NEWLY APPROVED ONCOHEMATOLOGIC DRUGS	6ER-003
	VISION RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC MACULAR OEDEMA AND AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR GROWTH FACTOR THERAPY OR DEXAMETHASONE	6ER-004
	DRUG WASTAGE: A HIDDEN COST OF CANCER CARE	6ER-005
	LABOUR PRODUCTIVITY GROWTH IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES UNDERGOING BIOLOGICAL OR JANUS KINASE INHIBITORS TREATMENT	6ER-006
	QUALITY, GAPS AND OPPORTUNITIES IN SMARTPHONE APPLICATIONS FOR PULMONARY HYPERTENSION: AN EVALUATION FROM HOSPITAL PHARMACISTS AND PATIENTS PERSPECTIVE	6ER-008
	PRESCRIBING PATTERNS AND EFFECTIVENESS OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION: A RETROSPECTIVE COHORT STUDY IN TAIWAN	6ER-009
	INVESTIGATING NEED AND APPROPRIATENESS FOR PHARMACIST-LED VACCINATION SERVICES WITHIN A HEALTHCARE SYSTEM	6ER-010
	AN ASSESSMENT OF PHARMACISTS’ CONFIDENCE AND BEHAVIORS IN DISPENSING OPIOID MEDICATIONS	6ER-011
	EVALUATION OF THE EFFECT OF CLOSED SYSTEM TRANSFER DEVICE SYRINGE ADAPTOR CONNECTION IN THE ISOLATOR ON CYTOTOXIC RESIDUE CONTAMINATION DURING INTRAVENOUS ADMINISTRATION	6ER-012
	ENHANCING PATIENT-CENTERED CARE THROUGH PREDICTIVE MODELING OF PATIENT-REPORTED OUTCOMES IN HOSPITAL PHARMACY SETTING	6ER-013
	ASSESSING ADHERENCE TO ESC/ERS GUIDELINES FOR VASOREACTIVITY TESTING AND PRESCRIPTION OF CALCIUM CHANNEL BLOCKERS IN PULMONARY HYPERTENSION PATIENTS	6ER-014
	RETRACTED PHARMACOLOGY ARTICLES: A CROSS-SECTIONAL STUDY USING THE RETRACTION WATCH DATABASE	6ER-015
	REAL-WORLD EFFECTIVENESS OF ALECTINIB AS FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER PATIENTS : AN EVIDENCE FROM TAIWAN	6ER-016
	FACTORS PREDICTIVE OF CLINICAL OUTCOME IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING OSIMERTINIB TREATMENT: A REAL-WORLD EXPERIENCE	6ER-017
	THE EFFECTIVENESS OF ADRENERGIC ALPHA ANTAGONISTS ON REDUCING RE-CATHETERIZATION RATES IN ADULTS WITH URINARY CATHETERS: A SYSTEMATIC REVIEW AND META-ANALYSIS.	6ER-018
	TREATMENT BEYOND PROGRESSION WITH PEMBROLIZUMAB IN ADVANCED NON-SMALL CELL LUNG CANCER	6ER-019
	WOULD CHATGPT PASS THE RESIDENT INTERNAL PHARMACIST EXAM?	6ER-020
	OPIOID-SPARING STRATEGIES FOR DISCHARGE ANALGESIA PRESCRIBING IN NON-COMPLEX SURGERIES – A MISSED OPPORTUNITY.	6ER-021
	KNOWLEDGE, ATTITUDE AND PRACTICE ABOUT PHARMACEUTICALS IN THE ENVIRONMENT AMONG HOSPITAL PHARMACISTS IN SPAIN	6ER-022
	A MULTI-SECTOR SIMULATED EXPERIENTIAL PRACTICE EVENT FOR YEAR ONE PHARMACY STUDENTS	6ER-023
	LYELL’S SYNDROME IN CAR-T TREATED PATIENTS: A CASE STUDY	6ER-024
	ANTIMICROBIAL ACTIVITY OF SUBCRITICAL CO2 EXTRACT OBTAINED FROM UNDERGROUND FERULA ASAFOETIDA L.	6ER-025
	THE IMPORTANCE OF PHARMACY DEPARTMENT CLINICAL TRIALS UNIT INTERVENTION IN A CENTRE OF REFERENCE FOR THE TREATMENT OF PARAMYLOIDOSIS	6ER-026
	ECONOMIC BENEFIT AND CLINICAL ADVANTAGES WITH THE INCLUSION OF PATIENTS IN CLINICAL TRIALS RELATED TO PARAMYLOIDOSIS	6ER-027
	REAL-WORLD TREATMENT PATTERN AND EFFECTIVENESS OF PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: A MULTI-INSTITUTIONAL STUDY IN TAIWAN	6ER-028
	A SYSTEMATIC REVIEW OF COMBINED POLY (ADP-RIBOSE) POLYMERASE INHIBITOR AND ANDROGEN RECEPTOR ANTAGONISTS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.	6ER-029
	EVALUATION OF A GROUP-BASED ONLINE INFORMED CONSENT CONVERSATION (ECONSENT) IN PARTICIPANTS FROM A VACCINATION CLINICAL TRIAL: A MIXED METHOD STUDY	6ER-030
	EXCLUSION OF PEOPLE LIVING WITH HIV FROM ONCOHAEMATOLOGICAL CLINICAL TRIALS WITH IMMUNE CHECKPOINT INHIBITORS	6ER-031
	ADJUSTED INDIRECT COMPARISON OF CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VS. IMMUNOTHERAPY ALONE IN THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH PD-L1≥50%	6ER-032
	ADJUSTED INDIRECT COMPARISON OF CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VS. IMMUNOTHERAPY ALONE IN THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH PD-L1≥1%	6ER-033
	EFFICACY OF NEOADJUVANT TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER IN EARLY STAGES: A SYSTEMATIC REVIEW	6ER-034
	EXAMINING THE PERCEPTIONS OF PHARMACISTS OF JOB SATISFACTION, ACHIEVMENTS, AND PREPRDNESS	6ER-035
	EVALUATION OF THE EFFICACY OF NEOADJUVANCE TREATMENT WITH IMMUNOTHERAPY IN EARLY STAGE BREAST CANCER: A SYSTEMATIC REVIEW	6ER-036
	PHARMACO-UTILISATION OF IBRUTINIB IN CLL: A SINGLE CENTRE STUDY	6ER-037
	ELABORATION OF A COMPETENCY FRAMEWORK FOR PATIENTS UNDERGOING PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE OR ATRIAL SEPTAL DEFECT	6ER-038
	PAIN MANAGEMENT: OPIOID USE IN HOSPITALS	6ER-039
	A TOOL PROPOSAL FOR IDENTIFYING THE RISK OF POLYPHARMACY IN NURSING HOMES FOR ELDERLY PEOPLE	6ER-040
	ROLE OF CHECKPOINT INHIBITORS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA	6ER-041
	THE DISASTER PREPAREDNESS AND MANAGEMENT OF HEALTHCARE PRACTITIONERS: A SYSTEMATIC REVIEW OF THE ASSESSMENT INSTRUMENTS	6ER-042
	DEVELOPING AND VALIDATING A DISASTER MANAGEMENT ASSESSMENT TOOL FOR HEALTHCARE PRACTITIONERS	6ER-043

27th Congress of the EAHP

National Poster Prize Winners

PDF Document	Poster Title	Poster Number
	DEVELOPING THE ROLE OF PRIMARY CARE CLINICAL PHARMACIST	NP-001
	“CAPSULE PHARMA”, AN INNOVATIVE DIGITAL TRAINING TOOL TO LEARN ABOUT IMPORTANT STERILE MEDICAL DEVICE (SMD) CONCEPTS	NP-002
	PHARMACEUTICAL INFUSION SCHEDULES AS A TOOL TO IMPROVE FLUID RESTRICTION IN PICU PATIENTS	NP-003
	RETROSPECTIVE STUDY ON INDIVIDUALISED MEDICATION OF DEMENTIA PATIENTS RECEIVING CHRONIC HOSPITAL CARES	NP-004
	SELF-ASSESSMENT ON THE IMPLEMENTATION OF RECOMMENDATIONS OF THE PERIOPERATIVE PROCESS: INFECTIOUS RISK MANAGEMENT IN SURGERY SETTING	NP-005
	IMMUNOTHERAPY IN SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER	NP-006
	RECOMMENDATIONS FOR ADMINISTRATION OF IMMUNOSUPPRESSANTS VIA ENTERAL FEEDING TUBE ACCORDING TO THEIR IN-VITRO ADMINISTRATION	NP-007
	EMERGENCY DEPARTMENT REVISIT SOCORE BASED ON PHARMACOTHERPAY	NP-008
	ASSESSMENT OF MEDICATION DISCREPANCIES BY PHARMACIST-LED MEDICATION RECONCILIATION AT ADMISSION : A PROSPECTIVE STUDY IN TRAUMATOLOGY	NP-009
	DEVELOPMENT OF A 2% LIDOCAINE GEL FOR LOCAL ANAESTHESIA OF THE EYE PRIOR TO INTRAVITREAL INJECTION	NP-010
	Around one-third of people with diabetes will develop foot ulcers in their lifetime	Student Science Award

Section 1: Introductory Statements and Governance

PDF Document	Poster Title	Poster Number
	ECONOMIC IMPACT GENERATED BY NATALIZUMAB OPTIMIZATION	1ISG-001
	MEDICATION WASTE IN AN ORTHOPAEDIC DEPARTMENT: EFFECT OF PATIENT’S OWN MEDICATION USE AND SELF-ADMINISTRATION DURING HOSPITALISATION AND THE VIEWS OF PATIENTS AND HOSPITAL STAFF	1ISG-002
	PROTOCOL FOR THE OPTIMISATION OF PHARMACEUTICAL VALIDATION IN HOSPITALIZED PATIENTS	1ISG-003
	HOME DELIVERY – EFFICIENCY, ECONOMY AND CUSTOMER SATISFACTION OUTCOMES – COMPARISON OF ASSISTANCE MODELS	1ISG-004
	DEPARTMENT COMPUTERISED PHARMACEUTICAL CABINET: RESULTS OF DEMATERIALIZATION AND TRACEABILITY OF DRUGS IN OBSTETRICS AND GYNECOLOGY	1ISG-005
	OPPORTUNITY TO STUDY ADHERENCE AND PERSISTENCE WITH HOME DELIVERY (HD) – REAL WORLD DATA (RWD) AND REAL WORLD EVIDENCE (RWE) ANALYSIS	1ISG-006
	OPPORTUNITIES FOR LOGISTIC REORGANISATION OF THE HOSPITAL PHARMACY WITH NEW CARE MODES: STOCK MANAGEMENT (SM) AND HOME DELIVERY (HD)	1ISG-007
	THE MULTIDISCIPLINARY ASSESSMENT OF RAPID ANTIGEN TESTS FOR THE DETECTION OF THE OMICRON VARIANT: THE ROLE OF THE HOSPITAL PHARMACIST IN A UNIVERSITY HOSPITAL	1ISG-008
	A FRAMEWORK FACILITATING ACCESS TO MEDICINES IN THE EUROPEAN UNION	1ISG-009
	PHARMACY STAFF SATISFACTION AND OPINION OF NEW WEBSITE APPLICATION FOR OUTPATIENT CARE	1ISG-010
	MANAGEMENT OF UNADMINISTERED THERAPIES: IMPACT OF PHARMACIST-DOCTOR COLLABORATION TO OPTIMIZE THE PROCESS OF PREPARING CANCER THERAPIES	1ISG-011
	COST-MINIMISATION ANALYSIS: PROPHYLACTIC TREATMENT OF HAEMOPHILIA TYPE A, WHAT TO CHOOSE BETWEEN FACTOR VIII, RECOMBINANT FACTORS VIII (MOROCTOCOG-ALFA AND OCTOCOG) AND EMICIZUMAB?	1ISG-012

Section 2: Selection, Procurement and Distribution

PDF Document	Poster Title	Poster Number
	USE AND COST EVOLUTION OF INFLIXIMAB AND ADALIMUMAB OVER 8 YEARS IN A TERTIARY HOSPITAL	2SPD-001
	COST SAVINGS IMPACT OF GENERICS: A LOCAL EXPERIENCE ON LENALIDOMIDE	2SPD-002
	ERRORS DETECTED IN THE TELEPHARMACY PROCEDURE	2SPD-003
	ECONOMIC EVALUATION AND BUDGET IMPACT FOR A REGIONAL HEALTH SERVICE ASSOCIATED WITH THE INCLUSION OF THE FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN A REGIONAL PHARMACOTHERAPEUTIC GUIDELINE	2SPD-004
	NEW CLOSED SYSTEM TRANSFER DEVICE CONTAINS REAL DRUG VAPOURS FOR UP TO 28 DAYS	2SPD-005
	ARE ALL BIOLOGIC AGENTS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS EQUIVALENT ALTERNATIVES?	2SPD-006
	USE OF DRUGS IN SPECIAL SITUATIONS	2SPD-007
	BUDGETARY IMPACT DUE TO THE REPLACEMENT OF ORIGINAL LENALIDOMIDE INTO GENERIC LENALIDOMIDE	2SPD-008
	AVOIDED COSTS FROM THE INCLUSION OF BREAST CANCER PATIENTS IN CLINICAL TRIALS	2SPD-009
	REVIEW OF THE ENVIRONMENTAL CRITERIA INTRODUCED IN THE TENDERING OF DRUGS, MEDICAL DEVICES AND NON-MEDICAL EQUIPMENT IN A HEALTH GROUP PROCUREMENT ORGANIZATION	2SPD-010
	COMPARATIVE EFFICACY OF EPTINEZUMAB, GALCANEZUMAB, FREMANEZUMAB AND ERENUMAB IN THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE	2SPD-011
	COMPARATIVE EFFICACY OF ABROCITINIB, BARICITINIB AND UPADACITINIB IN MONOTHERAPY FOR THE TREATMENT OF ATOPIC DERMATITIS	2SPD-012
	INTERVENTIONAL CARDIOLOGY: ANALYSIS OF STERILE MEDICAL DEVICE’S CONSUMPTION AND ASSESSMENT OF DIFFERING PRACTICES	2SPD-013
	COST STUDY: REUSABLE FLEXIBLE URETEROSCOPES VERSUS SINGLE-USE IN A HEALTHCARE FACILITY	2SPD-014
	INDIRECT COMPARISON OF ANIFROLUMAB VS BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS	2SPD-015
	COMPARATIVE EFFICACY OF BIMEKIZUMAB, IXEKIZUMAB AND BRODALUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS	2SPD-016
	TELEPHARMACY AND HOME DELIVERY PROGRAMME FOR OUTPATIENTS THROUGH THE COMMUNITY PHARMACY	2SPD-017
	BEZLOTOXUMAB: STRATEGIES TO REDUCE ECONOMIC IMPACT	2SPD-018
	EXPLORING ECONOMIC AND QUALITATIVE ASPECTS OF DRUG USE IN A PENITENTIARY INSTITUTE	2SPD-019
	IMPACT OF COVID-19 TREATMENT OPTIONS ON HOSPITAL PHARMACY’S WORKLOAD: LESSONS LEARNED	2SPD-020

Section 3: Production and Compounding

PDF Document	Poster Title	Poster Number
	PREPACKED BOXES FOR OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT) – A QUESTIONNAIRE SURVEY ON KNOWLEDGE, OPINION AND WISHES	3PC-001
	HAZARDOUS DRUG AND ANTIBIOTIC RESIDUE SURFACE CONTAMINATION – IS THERE A NEED TO REDUCE EXPOSURE?	3PC-002
	99m-Tc- HMPAO LABELED LEUKOCITES: STUDYING ACUTE INFECTION OUTBREAKS – NUCLEAR PHARMACIST IN NUCLEAR MEDICINE	3PC-003
	ECONOMIC SAVINGS OF ERENUMAB REDOSING IN A THIRD LEVEL HOSPITAL	3PC-004
	CLOSED SYSTEM TRANSFER DEVICE (CSTD) EXTENDS PRACTICAL IN-USE SHELF LIFE TO 28 DAYS AFTER FIRST PUNCTURE OF NON-PRESERVED SINGLE-USE-VIALS IN BOTH CONTROLLED AND UNCONTROLLED ENVIRONMENTS	3PC-005
	CONTAINER CLOSURE INTEGRITY TESTING AND PROCES VALIDATION OF CLOSED SYSTEM TRANSFER DEVICES FOR ASEPTIC RECONSTITUTION OF DRUG VIALS CONNECTED TO FLUID BAGS	3PC-006
	IMPACT OF A SUSTAINABILITY STRATEGY IN THE DEVELOPMENT OF STANDARDIZED NEONATAL PARENTERAL NUTRITION ON DEMAND	3PC-007
	SLOW ANAKINRA DESENSITIZATION PROTOCOL DESIGN FOR DELAYED HYPERSENSIBILITY REACTION	3PC-008
	CYCLOPHOSPHAMIDE SURFACE CONTAMINATION IN A ROBOTIC CHEMOTHERAPY COMPOUNDING PROCESS	3PC-009
	FORMULATION OF TACROLIMUS SOLUTION FOR SUBLINGUAL USE	3PC-010
	A VIRTUAL STERILISATION AREA : AN INTERACTIVE TRAINING TOOL	3PC-011
	IMPACT AND SATISFACTION IN DRUG ADDICTS ATTENTION CENTERS AFTER INCREASING THE STABILITY OF METHADONE ORAL SOLUTION	3PC-012
	FORMULATION AND ELABORATION OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF A MENINGEAL CARCINOMATOSIS	3PC-013
	METAMORPHINE INSTEAD OF POLYSUBSTANCE USE?	3PC-014
	IN-USE STABILITY OF COMIRNATY AND SPIKEVAX CLINICAL SOLUTIONS: PFIZER-BIONTECH AND MODERNA COVID-19 VACCINES. A COMPARATIVE STUDY FROM A HOSPITAL PHARMACY PERSPECTIVE	3PC-015
	DOES A HOSPITAL COMPRESSOR SYSTEM CONTINOUSLY DELIVER MEDICINAL AIR ACCORDING TO THE EUROPEAN PHARMACOPAEIA?	3PC-016
	IMPACT OF AGITATION ON PEMBROLIZUMAB (KEYTRUDA®) SAFETY AND EFFICACY: AGGREGATION AND FUNCTIONALITY.	3PC-017
	TIME TO AVAILABILITY OF INJECTABLE ANTICANCER DRUGS FOR OUTPATIENTS: REASSESSMENT IN A FRENCH COMPREHENSIVE CANCER CENTER	3PC-018
	INDIGO CARMINE SOLUTION AND ADRENALINE IN SUBMUCOSAL CHROMOENDOSCOPY	3PC-019
	CLOBETASOL PETROLATUM OINTMENT 0.015% FOR THE TREATMENT OF CUTANEOUS GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS: A CASE REPORT.	3PC-020
	AMPHOTERICIN AND COLISTIN GELS FOR NECROTIZING WOUNDS: GALENIC AND MICROBIOLOGICAL VALIDATION.	3PC-021
	FORMULATION AND QUALITY CONTROL OF A BISOPROLOL 0.5 MG/ML ORAL SOLUTION FOR PAEDIATRIC USE	3PC-022
	PATCH TESTS WITH ETHAMBUTOL 10%, ISONIAZID 15% AND PYRAZINAMIDE 25%: A CASE REPORT.	3PC-023
	THE PREPARATION PERSONALIZED OF IMMUNOGLOBULIN BAGS TO IMPROVE THE TREATMENT PATH OF NEUROLOGICAL PATIENTS	3PC-024
	OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT): AN EXAMPLE DURING THE COVID-19 HEALTH EMERGENCY.	3PC-025
	EFFECTIVENESS AND SAFETY OF INSULIN 1UI/ml EYE DROPS	3PC-026
	STABILITY OF TACROLIMUS ORAL SUSPENSION IN DISPOSABLE POLYPROPYLENE SYRINGE	3PC-027
	FORMULATION OF AN ORAL PLATELET LYSATE GEL TO TREAT CHRONIC GRAFT VERSUS HOST DISEASE ASSOCIATED ORAL MUCOSITIS. EFFECTIVENESS IN A SERIES OF CASES	3PC-028
	MANAGEMENT OF A CHEMOTHERAPY PRODUCTION AFTER A CYBER-ATTACK IN A PUBLIC HOSPITAL	3PC-029
	EVALUATION OF EXCIPIENTS USED IN PAEDIATRIC COMPOUNDED FORMULATIONS PRESCRIBED IN A NEONATAL INTENSIVE CARE UNIT	3PC-030
	A DELPHI METHOD TO STANDARDIZE THE PREPARATION OF AUTOLOGOUS SERUM EYE DROPS ?	3PC-031
	USE OF ORAL KETAMINE FORMULATION IN PATIENTS WITH CHRONIC REFRACTORY PAIN	3PC-032
	ECONOMIC IMPACT OF CENTRALIZING PEDIATRIC INTRAVENOUS ADMIXTURES	3PC-033
	USE OF A MIXTURE OF BLEOMYCIN, LIDOCAINE AND EPINEPHRINE IN THE TREATMENT OF KELOID SCARS.ON THE SUBJECT OF A CASE.	3PC-034
	GALENIC DEVELOPMENT OF A GENERIC SPECIALTY WITH CONVENTIONAL RELEASE BASED ON ACARBOSE	3PC-035
	CENTRALIZED AND PERSONALIZED PREPARATION OF INTRAVENOUS KETAMINE FOR PATIENTS WITH RESISTANT DEPRESSION	3PC-036
	LIQUID CHROMATOGRAPY MASS SPECTROMETRY ANALYSIS OF DOXORUBICIN AND EPIRUBICIN AFTER FREEZING	3PC-037

Section 4: Clinical Pharmacy Services

PDF Document	Poster Title	Poster Number
	EMICIZUMAB IN ACQUIRED HAEMOPHILIA TYPE A: A CASE REPORT.	4CPS-001
	SAFETY AND EFFECTIVENESS OF MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION AFTER TWO AND A HALF YEARS OF CLINICAL EXPERIENCE	4CPS-002
	EXPERIENCES WITH A BEST POSSIBLE MEDICATION HISTORY (BPMH) CONDUCTED BY PHARMACY STUDENTS IN THE HOSPITAL SETTING: A SCOPING REVIEW	4CPS-003
	TRENDS IN TREATMENTS DURING COVID-19 PANDEMIA IN A UNIVERSITY TERTIARY HOSPITAL	4CPS-004
	SUCCESSFUL TREATMENT OF OSTEOMYELITIS CAUSED BY DIFFICULT-TO-TREAT RESISTANT PSEUDOMONAS AERUGINOSA WITH CEFIDEROCOL AS MONOTHERAPY: A CASE REPORT	4CPS-005
	COMPLETE CLINICAL RESPONSE IN METASTATIC BREAST CANCER AFTER FRONT-LINE TREATMENT WITH RIBOCICLIB/TAMOXIFEN	4CPS-006
	TARGETING PATIENTS WITH PNEUMONIA BY COVID-19 THAT COULD BE BENEFICIATED BY COLCHICINE.	4CPS-007
	DOES COMORBIDITY AFFECT ADHERENCE TO INHALERS IN SEVERE ASTHMA PATIENTS TREATED WITH BIOLOGICS?	4CPS-008
	Δ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY : EVALUATION OF EFFECTIVENESS AND SAFETY	4CPS-009
	DUPILUMAB FOR THE TREATMENT OF ATOPIC DERMATITIS: EVALUATION OF EFFECTIVENESS AND SAFETY	4CPS-010
	CLINICAL AND ECONOMIC IMPACT OF PHARMACIST ANTIMICROBIAL INTERVENTIONS IN A SMALL HOSPITAL	4CPS-011
	PLATELET TO LYMPHOCYTE RATIO (PLR) AS BIOLOGICAL MARKER OF INTEREST IN INMUNOTHERAPY	4CPS-012
	TREOSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE. EFFICACY AND SAFETY.	4CPS-013
	COMPARISON OF TWO PROTOCOLS FOR THE ADMINISTRATION OF LEUCOVORIN RESCUES AFTER HIGH DOSE METHOTREXATE INFUSION OF 24 HOURS	4CPS-014
	ROLE OF CLINICAL PHARMACIST IN THE OPTIMISATION OF NIRMATRELVIR/RITONAVIR PRESCRIPTION IN THE EMERGENCY DEPARTMENT	4CPS-015
	PREDICTIVE PERFORMANCE OF GLOMERULAR FILTRATION RATE EQUATIONS BASED ON CYSTATIN C, CREATININE AND THEIR COMBINATION IN CRITICALLY ILL PATIENTS	4CPS-016
	REAL-WORLD EVIDENCE ON RHEUMATOID ARTHRITIS TREATMENT PERSISTENCE: JANUS KINASE INHIBITORS VERSUS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS.	4CPS-017
	EVOLUTION OF ANTIMICROBIAL USE IN COVID-19 PATIENTS	4CPS-018
	QUALITY ASSESSMENT OF THE EVIDENCE UNDERPINNING PHARMACIST-LED ANTIMICROBIAL STEWARDSHIPS INTERVENTIONS	4CPS-019
	TREATMENT PERSISTENCE AND DISCONTINUATION REASONS OF JANUS KINASE INHIBITORS IN A REAL-WORLD SETTING OF RHEUMATOID ARTHRITIS PATIENTS.	4CPS-020
	EFFECTIVENESS, PERSISTENCE, AND ADHERENCE OF BARICITINIB IN RHEUMATOID ARTHRITIS: LONG-TERM REAL-WORLD EVIDENCE STUDY	4CPS-021
	ADHERENCE TO EVOLOCUMAB AND ITS IMPACT ON LDL CHOLESTEROL REDUCTION	4CPS-022
	TOPICAL RAPAMYCIN IN RARE TUBEROUS SCLEROSIS DISEASE: LIPOSOMAL FORMULATION STABILITY	4CPS-023
	COMPARISON OF CHANGES IN CLINICAL VALUES OF INTENSIVE CARE PATIENTS AT VETERANS HOSPITAL ACCORDING TO VARIOUS FAT EMULSIONS FOR PARENTERAL NUTRITION	4CPS-024
	FREMANEZUMAB UTILISATION STUDY AND EFFECTIVENESS IN THE ‘REAL WORLD’	4CPS-025
	EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN REDUCING POTASSIUM CONCENTRATIONS IN HOSPITALISED PATIENTS	4CPS-026
	COST SAVINGS IMPACT AND EFFECTIVENESS OF OMALIZUMAB OPTIMISATION IN REFRACTORY CHRONIC URTICARIA.	4CPS-027
	DRUG BURDEN INDEX EVALUATION IN INSTITUTIONALIZED GERIATRIC PATIENTS AS A DEPRESCRIPTION STRATEGY	4CPS-028
	ECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES	4CPS-029
	IMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES	4CPS-030
	THERAPEUTIC DRUG MONITORING OF CEFTAZIDIME/AVIBACTAM ADMINISTERED BY CONTINUOUS INFUSION: PK/PD TARGET ACHIEVEMENT AND CLINICAL OUTCOMES	4CPS-031
	THE USE OF LEAN METHODOLOGY IN CLINICAL PHARMACOKINETICS – A RETROSPECTIVE ANALYSIS	4CPS-032
	EVALUATION OF THE EFFECTIVENESS OF REINDUCTION OR INTENSIFICATION WITH USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE	4CPS-033
	ANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-19	4CPS-034
	ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE	4CPS-035
	SUCCESSFUL TREATMENT OF POSTSURGICAL MENINGITIS CAUSED BY BACILLUS CEREUS: A CASE REPORT	4CPS-036
	INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN PSORIATIC ARTHRITIS	4CPS-037
	CHALLENGES RELATED TO TRANSITIONING FROM HOSPITAL TO TEMPORARY CARE AT A SKILLED NURSING FACILITY	4CPS-038
	CLINICAL AND ECONOMIC IMPACT OF MULTISWITCHING FROM ORIGINAL ADALIMUMAB TO BIOSIMILARS.	4CPS-039
	ELECTRONIC CLINICAL DECISION SUPPORT FOR PHARMACOTHERAPEUTIC INTERVENTIONS TO REDUCE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS	4CPS-040
	ASSESSMENT OF QUALITY OF LIFE IN PATIENTS UNDERGOING ANTIMIGRAINE TREATMENT	4CPS-041
	OFF-LABEL USE OF USTEKINUMAB IN NONBULLOUS CONGENITAL ICHTHYOSIFORM ERYTHRODERMA: A CASE REPORT	4CPS-042
	DRUG-DRUG INTERACTIONS WITH NIRMATRELVIR/RITONAVIR FOR COVID-19 AND THE ROLE OF HOSPITAL PHARMACISTS	4CPS-043
	EFFECTIVENESS AND SAFETY OF DIFFERENT INITIAL DOSES OF ARIPIPRAZOLE INTRAMUSCULAR DEPOT	4CPS-044
	ECOLOGICAL AND CLINICAL IMPACT OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME ON THE INCIDENCE OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE	4CPS-045
	A QUALITATIVE STUDY OF FEASABILITY AND ACCEPTABILITY OF A PHARMACY PRIORITISATION TOOLKIT BY A FRAILTY FOCUSED MULTIDICIPLINARY TEAM IN AN ACUTE HOSPITAL EMERGECY DEPARTMENT	4CPS-046
	IMPACT OF CORTICOSTEROID ON THE EFFECTIVENESS OF IMMUNOTHERAPY	4CPS-047
	ANALYSIS OF PAXLOVID® FOR THE TREATMENT OF COVID-19 IN ARAGÓN, SPAIN	4CPS-048
	TELEPHARMACY AND NEW HEALTHCARE MODELS: CLOSER TO PATIENTS	4CPS-049
	ANALYSIS OF REAL-LIFE USE OF IBRUTINIB AFTER RELAPSE TO CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA	4CPS-050
	IMPACT OF THE NEW ANTIEPILEPTIC DRUG MONITORING PROGRAMME ON THE ACTIVITY OF THE PHARMACY AND NEUROLOGY DEPARTMENTS	4CPS-051
	LONG-TERM MONITORING OF UREA AS TREATMENT FOR HYPONATREMIA ASSOCIATED TO INADEQUATE SECRETION OF ANTIDIURETIC HORMONE (ISADH)	4CPS-052
	KOUNIS SYNDROME SECONDARY TO METAMIZOLE: A CASE REPORT	4CPS-053
	USE OF INTRATHECAL LIPOSOMAL-AMPHOTERICIN B FOR CANDIDA MENINGITIS: A CASE REPORT.	4CPS-054
	EFFECTIVENESS AND SAFETY OF RIBOCICLIB IN THE FIRST LINE OF LUMINAL METASTATIC BREAST CANCER.	4CPS-055
	A CLINICAL AND COST ANALYSIS OF MEDICINES RECONCILIATION BY CLINICAL PHARMACISTS ON HOSPITAL DISCHARGE	4CPS-056
	SEARCHING FOR A TREATMENT FOR PERIPHERAL TISSUE ISCHEMIA IN NEWBORNS. A CASE REPORT.	4CPS-057
	SYMBALOO AS DIGITAL TOOL FOR HEMOPHILIA	4CPS-058
	EFFICACY AND SAFETY OF EARLY SWITCH TO ORAL ANTIBIOTHERAPY IN PNEUMOLOGY: PROPENSITY SCORE-MATCHED ANALYSIS	4CPS-059
	EFFECTIVENESS AND ECONOMIC ANALYSIS OF WEIGHT-BASED VERSUS FIXED DOSING OF PEMBROLIZUMAB IN NON SMALL CELL LUNG CANCER	4CPS-060
	APPLICATION OF PROPORTION OF DAY COVERED (PDC) TO EVALUATE ADHERENCE AND PERSISTENCE TO TREATMENT WITH FINGOLIMOD IN PATIENTS WITH MULTIPLE SCLEROSIS	4CPS-061
	EVALUATION AND FOLOW-UP OF PEDIATRIC PATIENT WITH SHORT BOWEL SYNDROME ON TREATMENT WITH TEDUGLUTIDE: CASE REPORT	4CPS-062
	USING MACHINE LEARNING TO PREDICT PHARMACEUTICAL INTERVENTIONS IN A HOSPITAL SETTING	4CPS-063
	EFFECTIVENESS OF RIBOCICLIB AND ABEMACICLIB AS FIRST LINE TREATMENT FOR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN.	4CPS-064
	SIMULATION OF THE IMPACT OF PHARMACOGENETIC MONITORING OF CYTOCHROME P450 2C19 IN PATIENTS ON CLOPIDOGREL TREATMENT	4CPS-065
	BIOLOGICAL TREATMENTS USED TO TREAT HIDRADENITIS SUPPURATIVA IN A TERTIARY HOSPITAL	4CPS-066
	A CROSS-SECTORAL PHARMACIST INTERVENTION FOR PATIENTS IN TRANSITION BETWEEN HOSPITAL AND GENERAL PRACTICE: A PILOT STUDY	4CPS-067
	CONDUCTION OF AN AUDIT TO REDUCE THE ECONOMIC LOSS DUE TO UNUTILIZED ONCOLOGICAL DRUG PREPARATIONS	4CPS-068
	EXPERIENCE OF ONCOHEMATOLOGY PATIENTS IN OUTPATIENT THERAPY WITH COMPREHENSIVE MEDICATION MANAGEMENT IN THE CONTEXT OF A COVID 19 PANDEMIC	4CPS-069
	THE CLINICAL PHARMACIST : AN ESSENTIAL ACTOR IN TIMES OF CRISIS	4CPS-070
	IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS	4CPS-071
	REAL-WORLD EXPERIENCE IN HEMOPHILLIA B PATIENTS AFTER SWITCHING TO FIX EXTENDED HALF LIFE USING PHARMACOKINETIC POBLACIONAL SOFTWARE AND MONOCOMPARTIMENTAL MODEL	4CPS-072
	ANALYSIS OF EFFECTIVENESS AND POSITIVE PREDICTIVE VALUE OF ANTIMICROBIAL STEWARDSHIP ALERTS USING A CLINICAL-DECISSION SUPPORT SYSTEM	4CPS-073
	EFFICACY AND SAFETY OF SOTROVIMAB: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY IN A FRENCH HOSPITAL	4CPS-074
	PERSISTENCE AND COST ANALYSIS OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIASIS	4CPS-075
	EFFECTIVENESS AND TOLERABILITY OF CYCLIN-DEPENDENT KINASE INHIBITOR TREATMENT IN METASTATIC BREAST CANCER: REAL-LIFE DATA.	4CPS-076
	CLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS TREATED WITH DORAVIRINE	4CPS-077
	ASSESSMENT OF THE QUALITY OF A HOSPITAL’S CLINICAL TRIAL INITIATION VISIT	4CPS-078
	COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM ADMINISTERED BY INTERMITTENT INFUSION VERSUS CONTINUOUS INFUSION	4CPS-079
	OPTIMIZATION OF ANTIRETROVIRAL THERAPY: RESULTS AFTER SIMPLIFICATION TO BITHERAPY WITH DOLUTEGRAVIR/LAMIVUDINE OR DOLUTEGRAVIR/RILPIVIRINE.	4CPS-080
	EVALUATION OF EFFECTIVENESS, SAFETY AND ADHERENCE OF PRE-EXPOSURE PROPHYLAXIS AGAISNT HIV	4CPS-081
	MOST FREQUENT ERRORS IN THE INHALATION TECHNIQUE OF ASTHMATIC CHILDREN	4CPS-082
	CREATININE AND CYSTATIN-BASED ESTIMATED RENAL FUNCTION IN VANCOMYCIN MONITORING	4CPS-083
	EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH VERY HIGH VS HIGH PD-L1 EXPRESSION	4CPS-084
	PHARMACEUTICAL INTERVENTIONS IN A NEONATOLOGY UNIT	4CPS-085
	COMPARISON OF A TRADITIONAL ELISA TECHNIQUE VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.	4CPS-086
	PERSISTENCE IN THE METHADONE MAINTENANCE PROGRAMME AND ITS RELATIONSHIP WITH THE MEDICATION REGIMEN COMPLEXITY INDEX IN OPIOID DEPENDENT PATIENTS	4CPS-087
	CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY IN NON-SMALL CELL LUNG CANCER TREATED WITH NIVOLUMAB	4CPS-088
	CURRENT STATUS OF HEPATITIS C VIRUS INFECTION	4CPS-089
	A REVIEW OF PHARMACY HOMECARE SERVICES WITHIN A GROUP OF UK HOSPITAL PHARMACIES	4CPS-090
	WHAT YOU NEED TO KNOW ABOUT BRUGADA SYNDROME IF YOU ARE A HOSPITAL PHARMACIST	4CPS-091
	STATISTICAL RELATIONSHIP BETWEEN BIOMARKERS WITH PROGNOSTIC VALUE IN ANTI-PDL1 TREATMENTS IN CANCER PATIENTS	4CPS-092
	POLYPHARMACY AND INAPPROPRIATE DRUGS IN PATIENTS WITH OROPHARYNGEAL DYSPHAGIA	4CPS-093
	ANALYSIS OF INTERVENTIONS ON ANTIBIOTIC PRESCRIPTIONS BY THE ANTIMICROBIAL STEWARDSHIP PROGRAMS AT THE EMERGENCY DEPARTMENT	4CPS-094
	INFUSION AUDIT IN HEMATOLOGY: IMPORTANCE OF EVALUATION AND OPTIMIZATION OF PROFESSIONAL PRACTICES	4CPS-095
	EVOLUTION OF SELECTIVE IMMUNOMODULATE THERAPY IN SPECIAL SITUATIONS	4CPS-096
	COMPARATIVE EFFECTIVENESS OF RISANKIZUMAB AND SECUKINUMAB IN MODERATE TO SERIOUS PSORIASIS.	4CPS-097
	NIRMATRELVIR-RITONAVIR EFFECTIVENESS ANALYSIS AND INTERACTION PROFILE ANALYSIS	4CPS-098
	NINTEDANIB AND PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS: COMPARATIVE EFFECTIVENESS AND SAFETY IN A THIRD-LEVEL HOSPITAL	4CPS-099
	VALIDITY, RELIABILITY AND USER-PRACTICABILITY OF A CLASSIFICATION TOOL FOR DRUG-RELATED PROBLEMS AND PHARMACIST INTERVENTIONS WITHIN AN UPPER AUSTRIAN HOSPITAL TRUST	4CPS-100
	CAUSALITY OF ADVERSE DRUG REACTIONS IN HIV-PATIENTS TREATED WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE	4CPS-101
	DRUG RELATED PROBLEMS SECONDARY TO HEPARIN TREATMENT IN PATIENTS DISCHARGED FROM THE EMERGENCY DEPARTMENT	4CPS-102
	PHARMACOKINETIC INTERACTION STUDY OF OSIMERTINIB AND DIGOXIN: A CASE REPORT	4CPS-103
	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN A UNIT DOSE AREA	4CPS-104
	CEFIDEROCOL TREATMENT IN COVID-19 POSITIVE PATIENTS CO-INFECTED WITH PAN-RESISTANT PSEUDOMONAS AERUGINOSA	4CPS-105
	BEDSIDE CHECK OF MEDICATION APPROPRIATENESS (BED-CMA) AS A RISK-BASED TOOL FOR BEDSIDE CLINICAL PHARMACY SERVICES: A PROOF-OF-CONCEPT STUDY AT THE TRAUMA SURGERY WARD	4CPS-106
	EFFECT OF PATIENT BODY WEIGHT ON THE PHARMACOKINETIC BEHAVIOR OF AMIKACIN	4CPS-107
	PATIENT AND PHYSICIANS’S SATISFACTION WITH CLINICAL PHARMACY SERVICES ON A HEMATOLOGY WARD IN A LARGE TERTIARY CARE HOSPITAL	4CPS-108
	THERAPEUTIC DRUG MONITORING OF VANCOMYCIN IN ONCOLOGIC AND HEMATOLOGIC PATIENTS: REAL-WORLD DATA	4CPS-109
	ASSOCIATION BETWEEN BASELINE CHARACTERISTICSTS AND FIRST LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER PATIENTS	4CPS-110
	IMPORTANCE OF IMPLEMENTING A CLINICAL PHARMACOKINETIC UNIT IN HOSPITAL PHARMACY SERVICE	4CPS-111
	SURVEY OF DIETARY SUPPLEMENT USE AND VACCINATION STATUS AMONG RHEUMATOID ARTHRITIS PATIENTS DURING THE COVID-19 PANDEMIC	4CPS-112
	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS AND ACTIVITY IN THE ARTHROPATHY PHARMACEUTICAL CARE PRACTICE IN A REGIONAL HOSPITAL	4CPS-113
	DEVELOPMENT AND PROSPECTIVE VALIDATION OF A PREDICTION MODEL TO IDENTIFY CLINICALLY RELEVANT MEDICATION DISCREPANCIES AT THE EMERGENCY DEPARTMENT	4CPS-114
	DEVELOPMENT AND IMPLEMENTATION OF A REVIEW PROGRAMME ASSISTED BY THE PHARMACIST TO IMPROVE THE ADEQUACY OF TREATMENT IN POLYMEDICATED PATIENTS IN HOSPITAL OUTPATIENT SETTING	4CPS-115
	THE EFFICIENCY AND COST-EFFECTIVENESS OF HEALTHCARE AND NUTRITIONAL INTERVENTIONS IN THE MANAGEMENT OF POST-STROKE OROPHARYNGEAL DYSPHAGIA, RESULTS OF A SYSTEMATIC REVIEW	4CPS-116
	USE OF ERYTHROMYCIN AS PROKINETIC IN CRITICALLY HOSPITALIZED PATIENTS	4CPS-117
	HEALTH OUTCOMES IN A COHORT OF HIV+ PATIENTS STRATIFIED USING THE KAISER PERMANENTE PYRAMID POPULATION-BASED RISK STRATIFICATION MODEL	4CPS-118
	PNEUMONOLOGY-PHARMACY COLLABORATION IN THE PHARMACOTHERAPEUTIC OPTIMIZATION OF MONOCLONAL ANTIBODIES IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA	4CPS-119
	ADVERSE EFFECTS OF ANTIRETROVIRALS: EXPERIENCE OF PATIENTS. «TALK ABOUT IT TO BETTER MANAGE IT»	4CPS-120
	ANALYSIS OF THE USE OF INTRAVENOUS IRON IN OUTPATIENTS	4CPS-121
	CLINICAL FOLLOW-UP IN PATIENTS WITH MIGRAINE AFTER DISCONTINUATION OF PROPHYLACTIC BIOLOGICAL TREATMENT: A REAL-WORLD EXPERIENCE	4CPS-122
	CASE-CONTROL STUDY ON THE ASSOCIATION BETWEEN NOSOCOMIAL BLOODSTREAM INFECTIONS AND GLUCOCORTICOIDS, TOCILIZUMAB, SYSTEMIC ANTIBIOTICS, MECHANICAL VENTILATION AND LENGTH OF HOSPITAL STAY IN COVID-19 HOSPITALISED PATIENTS	4CPS-123
	EFFICACY AND SAFETY OF ERENUMAB IN A SECOND-LEVEL HOSPITAL	4CPS-124
	PREEXPOSURE PROPHYLAXIS IN MEN AT HIGH RISK FOR HIV-1 INFECTION	4CPS-125
	LINEZOLID STUDY USE AND ASSESSMENT THE APPROPRIATENESS OF ITS PRESCRIPTION IN A REGIONAL HOSPITAL	4CPS-126
	PHARMACOKINETIC MONITORING OF VANCOMYCIN, GENTAMICIN AND AMIKACIN IN PAEDIATRIC POPULATION	4CPS-127
	CLINICAL PRACTICE: ANTI-VEGF THERAPY FOR RESISTANT MACULAR EDEMA.	4CPS-128
	REAL-LIFE EFFECTIVENESS AND SAFETY OF NIRAPARIB AND OLAPARIB IN HIGH-GRADE OVARIAN CANCER	4CPS-129
	EVALUATION OF TIXAGEVIMAB-CILGAVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19	4CPS-130
	SOCIAL FUNCTION OF THE TELEPHARMACY: A SOCIOECONOMIC ANALYSIS	4CPS-131
	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS REGARDING ADMISSION RECONCILIATION	4CPS-132
	SAFETY AND EFFECTIVENESS OF GUSELKUMAB ON MODERATE TO SEVERE PLAQUE PSORIASIS	4CPS-133
	PERSISTENCE AND SHIFT IN THE TREATMENT OF PSORIASIS IN THE PERIOD 2019 – 2021	4CPS-134
	MELANOMA ADJUVANT THERAPY: from trials to clinical practice215	4CPS-135
	STANDARD FIRST DAY OF LIFE CENTRAL PARENTERAL NUTRITION, EXPERIENCE IN REAL CLINICAL PRACTICE	4CPS-136
	EVALUATING THE POTENTIAL CLINICAL AND ECONOMIC IMPACT OF CHEMOTHERAPY PRESCRIBING BY PHARMACISTS AT A UNIVERSITY TEACHING HOSPITAL	4CPS-137
	USE OF SODIUM ZIRCONIUM CYCLOSILICATE IN HYPERKALEMIC EMERGENCIES	4CPS-138
	THE PHARMACEUTICAL NEWSLETTER AS AN INFORMATION TOOL: USEFUL OR FUTILE ?	4CPS-139
	MEDICAL CANNABIS: PRESCRIPTION ANALYSIS IN TERMS OF FORMULATION AND THERAPEUTIC NEED IN AN HOSPITAL PHARMACY	4CPS-140
	PHARMACEUTICAL INTERVENTIONS IN A MEDICAL EMERGENCY DEPARTMENT: 6-MONTHS EXPERIENCE	4CPS-141
	EVALUATION OF PREMEDICATION USE IN ADVERSE DRUG REACTIONS OCCURENCE IN PATIENTS WHO RECEIVED INFLIXIMAB TO TREAT INFLAMMATORY BOWEL DISEASE	4CPS-142
	CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA FOLLOWING IMMUNE CHECKPOINT INHIBITION FOR SOLID TUMORS: TWO CASE REPORTS AND LITERATURE STATE OF THE ART.	4CPS-143
	EXPERIENCE OF USING REMDESIVIR IN THE TREATMENT OF PATIENTS WITH SARS-COV2 INFECTION	4CPS-144
	CONSENSUS VALIDATION OF A SCREENING TOOL FOR CARDIOVASCULAR PHARMACOTHERAPY IN GERIATRIC PATIENTS: THE RASP_CARDIO LIST	4CPS-145
	‘REAL WORLD’ EXPERIENCE OFELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN THE TREATMENT OF CYSTIC FIBROSIS: EFFECTIVENESS AND SAFETY EVALUATION	4CPS-146
	REAL WORLD DATA (RWD) ANALYSIS ON USE OF IMMUNECHECKPOINT INHIBITORS (ICI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)	4CPS-147
	USE OF ANTIVIRALS AUTHORIZED FOR THE TREATMENT OF COVID-19 IN PATIENTS NOT SUBJECT TO HOSPITAL ADMISSION	4CPS-148
	PAIN MANAGEMENT IN MENTAL HEALTH.	4CPS-149
	THE ROLE OF CLINICAL PHARMACIST IN EMERGENCY DEPARTMENT	4CPS-150
	ACETYLSALICYLIC ACID DESENSITIZATION IN PATIENTS WITH CORONARY ARTERY SYNDROME: LITERATURE REVIEW, RETROSPECTIVE ANALYSIS AND PATIENT FOLLOW-UP PROCEDURE IN AN ITALIAN CARDIOLOGICAL CENTER	4CPS-151
	PERSISTENT CYTOPENIA AFTER CAR-T CELLS: TREATMENT WITH ELTROMBOPAG. A CASE REPORT.	4CPS-152
	OFF-LABEL USE OF KETAMINE FOR RESISTANT DEPRESSION: ROLE OF THE HOSPITAL PHARMACIST	4CPS-153
	IFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITS: INCIDENCE IN A PATIENT SAMPLE AND POSSIBLE CHEMIOTHERAPY PROTOCOL REVIEW	4CPS-154
	CREATION AND VALIDATION OF A MEDICATION REVIEW SUPPORT TOOL FOR POTASSIUM CHLORIDE INJECTION (KCl-inj) PRESCRIPTIONS	4CPS-155
	ANALYSIS OF EFECTIVENESS AND COSTS OF DRUG THERAPY PRESCRIBED IN SPECIAL SITUATIONS IN OUR HOSPITAL	4CPS-156
	COMPARISON OF THE EFFECTIVENESS BETWEEN INTERLEUKIN-23 INHIBITORS FOR TREATMENT OF PSORIASIS IN A THIRD LEVEL HOSPITAL	4CPS-157
	IMPROVEMENT IN PATIENT CARE BY PHARMACIST PHONE CALL AFTER STARTING TREATMENT	4CPS-158
	ESTIMATING RENAL FUNCTION FOR DRUG DOSING: CORRELATION BETWEEN CKD-EPI AND COCKCROFT-GAULT IN AN ELDERLY POPULATION	4CPS-159
	REAL-WORLD PERSISTENCE WITH DOLUTEGRAVIR/LAMIVUDINE VERSUS BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE AMONG HUMAN IMMUNODEFICIENCY VIRUS PATIENTS	4CPS-160
	NEGATIVE PRESSURE WOUND THERAPY IMPORTANCE IN WOUND CARE	4CPS-161
	TRIPLE WHAMMY DRUG-DRUG INTERACTION: CLINICAL RELEVANCE AND RESULTS OF PHARMACEUTICAL INTERVENTION.	4CPS-162
	CYTOCHROME P450 2C19 GENOTYPING FOR PERSONALISATION OF PROTON PUMP INHIBITOR THERAPY	4CPS-163
	ADEQUACY REVIEW IN THE USE OF DAPAGLIFLOZIN FOR THE TREATMENT OF HEART FAILURE.	4CPS-164
	ADAPTATION OF MARKETED PARENTERAL NUTRITION TO THE NEEDS OF A HOSPITAL.	4CPS-165
	IMPLEMENTATION OF A LINEZOLID PHARMACOKINETIC MONITORING PROGRAMME	4CPS-166
	CURRENT TRENDS IN THE USE OF CHECK-POINT INHIBITORS FOR NON-SMALL CELL LUNG CANCER	4CPS-167
	RESULTS OF THE USE OF GALCANEZUMAB IN ROUTINE CLINICAL PRACTICE	4CPS-168
	PHYSICOCHEMICAL CHARACTERIZATION OF ORAL LIQUID FORMS AND REVIEW OF THE LITERATURE FOR SAFE AND EFFECTIVE ADMINISTRATION BY ENTERAL FEEDING TUBES	4CPS-169
	THE HOSPITAL PHARMACIST ROLE IN MULTIDISCIPLINARY TEAM DURING THE VACCINATION CAMPAIGN	4CPS-170
	METHADONE DRUG-DRUG INTERACTIONS POTENTIALLY RELATED TO CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE	4CPS-171
	BRODALUMAB’S EFFECTIVENESS ON MODERATE TO SEVERE PLAQUE PSORIASIS IN REAL PRACTISE	4CPS-172
	EVALUATION OF INCLUSION CRITERIA OF OUTPATIENTS INCLUDED AT HOSPITAL MEDICATION DISPENSING PROGRAMME THROUGH COMMUNITY PHARMACIES	4CPS-173
	EFFECTIVITY AND SAFETY OF CYCLIN-DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER PATIENTS	4CPS-174
	SEPSIS CODE: IMPROVING OUTCOMES FOR PATIENTS WITH SEPSIS	4CPS-175
	EVALUATION OF NIRMATRELVIR/RITONAVIR USE AND EFFECTIVENESS	4CPS-176
	OPTIMIZATION OF THE THERAPEUTIC MANAGEMENT OF PATIENTS ON ECMO IN THE PEDIATRIC INTENSIVE CARE UNIT	4CPS-177
	DURABILITY OF TREATMENT AND REASONS FOR DISCONTINUATION OF DIMETHYL FUMARATE AND TERIFLUNOMIDE IN PATIENTS WITH MULTIPLE SCLEROSIS	4CPS-178
	REVERSAL OF ANTICOAGULATION IN ORTHOGERIATRIC PATIENTS WITH HIP FRACTURE REQUIRING EARLY SURGICAL INTERVENTION	4CPS-179
	VANCOMYCIN: CONCORDANCE OF DOSAGE ADJUSTMENT ACCORDING TO MINIMUM PLASMA CONCENTRATION AND AREA UNDER THE CURVE/MINIMUM INHIBITORY CONCENTRATION	4CPS-180
	FOLLOW-UP OF EXPOSED NEWBORNS TO HIV IN PREGNANCY IN A TERTIARY HOSPITAL	4CPS-181
	EXPERIENCE OF DISCONTINUATION TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE	4CPS-182
	EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN REAL LIFE SETTING	4CPS-183
	WHAT IS THE ADDITIONNAL VALUE OF PHARMACEUTICAL INTERVENTIONS ON [123I]-METAIODOBENZYLGUANIDINE SCINTIGRAPHY?	4CPS-184
	COMPOUNDED INSULIN EYE DROPS: POPULATION CHARACTERISTICS, USE IN CLINICAL PRACTICE AND SAFETY	4CPS-185
	EFFECTIVENESS AND SAFETY OF CILGAVIMAB/TIXAGEVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19	4CPS-186
	PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH MONOCLONAL ANTIBODIES FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19	4CPS-187
	QUALITY OF LIFE IN PATIENTS ON GALCANEZUMAB LONG TERM TREATMENT	4CPS-188
	ANALYSIS OF MEDICATION PERSISTANCE IN MIGRAINE PATIENTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES	4CPS-189
	ANALYSIS OF IBRUTINIB DOSE REDUCTION IN PATIENTS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA. ARE WE DOING IT RIGHT?	4CPS-190
	IMPACT OF THE COVID-19 PANDEMIC ON THE ADHERENCE OF HIV PATIENTS	4CPS-191
	ANALYSIS OF ADHERENCE AND ASSOCIATED RISK FACTORS IN MULTIPLE SCLEROSIS PATIENTS UNDER DISEASE-MODIFYING THERAPY	4CPS-192
	SUITABILITY OF THE DUAL ANTIPLATELET THERAPY TO THE GUIDELINES OF EUROPEAN SOCIETY OF CARDIOLOGY IN ACUTE CORONARY SYNDROME	4CPS-193
	BASELINE AUDIT OF POTENTIAL TO OPTIMISE THERAPY THROUGH USE OF SGLT2i IN A COHORT OF PATIENT ADMITTED WITH AN ACUTE MYOCARDIAL INFARCTION	4CPS-194
	E-LUNGING: EVALUATION OF AN E-LEARNING PROGRAM INTENDED FOR HEALTHCARE PROFESSIONALS REGARDING THE MEDICATION OF LUNG TRANSPLANT PATIENTS	4CPS-195
	POTENTIALLY INAPPROPIATE MEDICATIONS AND POTENTIALLY PRESCRIBING OMISSIONS IN OLDER PEOPLE LIVING WITH HIV	4CPS-196
	CONCOMITANT USE OF PROTON PUMP INHIBITORS AND PALBOCICLIB: ¿IS THERE A REAL IMPACT ON RESPONSE?	4CPS-197
	ANALYSIS OF ANTIPSYCHOTIC DRUGS USE AT A SPANISH TERTIARY HOSPITAL	4CPS-198
	PHARMACO-ECONOMIC IMPACT OF DRUG INTOXICATIONS IN CHILDREN	4CPS-199
	SUSTAINING A PHARMACEUTICAL DECISION SUPPORT SYSTEM BY DETERMINING THE CLINICAL RISK’S LEVEL OF DETECTED DRUG-RELATED PROBLEMS	4CPS-200
	PHARMACEUTICAL CARE TO OPTIMIZE TREATMENT FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A PRISON	4CPS-201
	THE USEFULNESS OF A PHARMACY RESIDENT STAGE IN THE CRITICAL CARE UNIT	4CPS-202
	ANTIBIOTIC STEWARDSHIP PROGRAMME INTERVENTIONS IN A THIRD LEVEL HOSPITAL IN SPAIN: A ONE-YEAR REVIEW	4CPS-203
	NATIONAL SURVEY ON CLONIDINE PRESCRIBING PRACTICES IN COMPLEX TRAUMA IN CHILD PSYCHIATRY	4CPS-204
	PHARMACIST’S INTERVENTION IN THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH HEART FAILURE – AN OPPORTUNITY FOR IMPROVEMENT	4CPS-205
	EVALUATION OF IRON CARBOXYMALTOSE VS IRON SUCROSE ADMINISTRATION FOR THE CONTROL OF ANAEMIA IN HOSPITALISED PATIENTS	4CPS-206
	PHARMACEUTlCAL INTERVENTIONS IN AN INTENSIVE CARE UNIT OF EMERGENCY TRAUMA	4CPS-207
	TELEPHARMACY INTERVENTIONS IN PATIENTS WITH CHRONIC DISEASES	4CPS-208
	EXPERIENCE OF THE NOCEBO EFFECT IN PATIENTS WITH SWITCH TO BIOSIMILARS IN RHEUMATOID ARTHRITIS.	4CPS-209
	EFFICACY OF MONOCLONAL ANTIBODIES TO PREVENT PROGRESSION TO SEVERE COVID-19 DISEASE: REAL-LIFE DATA OF A UNIVERSITY HOSPITAL	4CPS-210
	DESIGN AND VALIDATION OF A QUESTIONNAIRE IN ARABIC LANGUAGE EVALUATING CHRONIC RENAL FAILURE PATIENTS’S KNOWLEDGE	4CPS-211
	SPECIALIST PHARMACIST-LED MULTIDISCIPLINARY CARE PATHWAY FOR OPTIMISING LIPID THERAPY – SIX MONTHS INTERIM ANALYSIS	4CPS-212
	CHARACTERISTICS OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN VERSUS KAWAZAKI ON CLINICAL ASPECTS, SPECIFICITIES AND TREATMENT	4CPS-213
	REAL-LIFE RESULTS ON THE USE OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER	4CPS-214
	DESCRIPTION OF THE PRE-EXPOSURE PROPHYLAXIS COVERAGE AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS.	4CPS-215
	OFF-LABEL USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN JEHOVAH’S WITNESS PATIENTS WITH HIP FRACTURE SUBJECTED TO MAJOR ORTHOPAEDIC SURGERY: A THREE CASES REPORT	4CPS-216
	THE USE OF CYSTIC FIBROSIS CONDUCTANCE REGULATOR MODULATORS IN PATIENTS WITH RARE MUTATION	4CPS-217
	TNF GENE POLYMORPHISMS PREDICTORS OF RESPONSE TO ANTI-TNF DRUGS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS	4CPS-218
	AGAMENON-SEOM MODEL FOR THE PREDICTION OF SURVIVAL IN PATIENTS WITH HER2-POSITIVE ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA RECEIVING TRASTUZUMAB-BASED FIRST-LINE TREATMENT	4CPS-219
	COMPARATIVE ANALYSIS OF SKIN TOXICITY ON PATIENTS WITH METASTATIC COLON CANCER TREATED WITH EPIDERMAL GROWTH RECEPTOR BLOCKING DRUGS.	4CPS-220
	ASSESSMENT OF CLINICAL BENEFIT OF CANCER TREATMENTS ACCORDING TO THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SCALE	4CPS-221
	HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED > 55 YEARS WITH ACUTE MYELOID LEUKAEMIA	4CPS-222
	BOTULINUM TOXIN TYPE A: THE NON-INVASIVE SUCCESS FOR OVERACTIVE BLADDERS	4CPS-223
	IMPACT OF AUGMENTED RENAL CLEARANCE ON ANTIMICROBIAL DOSING IN SEVERELY BURNED PATIENTS	4CPS-224
	HEALTH IMPACT OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH BIOLOGICAL AGENTS FROM THE PATIENT’S PERSPECTIVE: A CROSS-SECTIONAL STUDY USING PATIENT REPORTED OUTCOME MEASURES (PROMs)	4CPS-225
	CONTINUOUS INFUSION OF VANCOMICYN: WHO ARE THE PATIENT CANDIDATES AND HOW SAFE IT IS?	4CPS-226
	REAL WORLD EVIDENCE OF THE USE OF DEFIBROTIDE FOR PROPHYLAXIS OF VENO-OCCLUSIVE DISEASE AFTER POST-HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN	4CPS-227
	HIGH DOSE PHENOBARBITAL COMA IN PAEDIATRIC REFRACTORY STATUS EPILEPTICUS	4CPS-228
	THE ADDED VALUE OF A NATIONAL ELECTRONIC HEALTH RECORD FOR THE BEST POSSIBLE MEDICATION HISTORY OBTAINED BY A CLINICAL PHARMACIST	4CPS-229
	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED <60 YEARS WITH ACUTE MYELOID LEUKEMIA	4CPS-230
	EVALUATION OF CLINICAL DATA OF PATIENTS TREATED WITH ANTI-PCSK9 DRUGS IN TWO HEALTH DISTRICTS	4CPS-231
	COMPARATIVE EFFICACY OF RISANKIZUMAB AND GUSELKUMAB IN MODERATE TO SEVERE PLAQUE PSORIASIS	4CPS-232
	PD-L1 EXPRESSION AND HISTOLOGICAL TYPE AS PREDICTORS OF RESPONSE IN METASTASIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PEMBROLIZUMAB IN FIRST LINE	4CPS-233
	DEVELOPMENT AND VALIDATION OF A RAPID HIGH PERFORMANCE CHROMATOGRAPHY METHOD (HPLC) FOR THE DETERMINATION OF LINEZOLID IN HUMAN PLASMA	4CPS-234
	IMPACT OF TELEPHARMACY ON BIOLOGIC THERAPIES ADHERENCE AND CLINICAL OUTCOMES IN PATIENTS WITH PSORIASIS	4CPS-235
	LOSS TO FOLLOW-UP FACTORS OF PEOPLE LIVING WITH HIV	4CPS-236
	HYPERKALEMIA AND RISK FACTORS: SCREENING AND ASSESSSMENT IN HOSPITAL PATIENTS.	4CPS-237
	PROFILE OF ELDERLY PATIENTS AT HIGH FALL RISK AND POLYPHARMACY IN THE EMERGENCY DEPARTMENT.	4CPS-238
	POPULATION PHARMACOKINETICS OF ISAVUCONAZOLE BASED ON PHAMACOGENETICS IN IMMUNOSUPPRESSED PATIENTS	4CPS-239
	FINGOLIMOD: ANALYSIS OF USE AND SAFETY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS	4CPS-240
	FINAL VALIDITY OF A TOOL FOR RATING SIGNIFICANCE OF PHARMACISTS’ CLINICAL CONTRIBUTIONS IN HOSPITAL	4CPS-241
	ISAVUCONAZOLE TREATMENT IN TWO PEDIATRIC PATIENTS DURING EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: THE ROLE OF THERAPEUTIC DRUG MONITORING.	4CPS-242
	DELAYED HIV TREATMENT AND FACTORS ASSOCIATED	4CPS-243
	ANALYSIS AND COMPARISON OF OLANZAPINE ADMINISTRATION IN SMOKING AND NON-SMOKING PATIENTS	4CPS-244
	PREVENTION OF REFEEDING SYNDROME IN PATIENTS ON PARENTERAL NUTRITION: A REVIEW OF APPROPRIATENESS	4CPS-245
	TREATMENT AND NURSING CARE OF MUCORMYCOSIS IN PAEDIATRICS: A CASE REPORT	4CPS-246
	INITIATIVES TO IMPROVE THE MANAGEMENT OF PATIENTS WITH HEREDITARY ANGIOEDEMA BY HOSPITAL PHARMACY	4CPS-247
	THERAPEUTIC DRUG MONITORING OF LINEZOLID IN SOFT-TISSUE AND OSTEOARTICULAR INFECTIONS: A RETROSPECTIVE ANALYSIS	4CPS-248
	RELATIONSHIP BETWEEN RENAL FUNCTION AND ERTAPENEM PLASMA CONCENTRATION IN ADULT PATIENTS.	4CPS-249
	EXPERIENCE OF TECOVIRIMAT AND CIDOFOVIR USE IN A PATIENT WITH MONKEYPOX: A CASE REPORT	4CPS-250
	HEREDITARY ANGIOEDEMA: IMPACT OF THE BURDEN OF DISEASE IN SPAIN	4CPS-251
	OPTIMIZATION OF ERTAPENEM POSOLOGY IN A CRITICALLY ILL PATIENT BY THERAPEUTIC DRUG MONITORING: A CASE REPORT	4CPS-252
	DESCRIPTIVE STUDY OF THE ONCOLOGY AND HAEMATOLOGY POPULATION, DIAGNOSIS, AND IMMUNOTHERAPY IN PATIENTS OVER 65 YEARS OLD IN A THIRD LEVEL HOSPITAL	4CPS-253
	DAPAGLIFOZIN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE	4CPS-254
	ANTIPARKINSONIAN MEDICATION RECONCILIATION: HOW PREVENTING MEDICATION ERRORS PROMOTES THERAPEUTIC QUALITY AND SAFETY	4CPS-255
	ENHANCING THE SAFETY OF INJECTABLE CYTOTOXIC CHEMOTHERAPY AT A TERTIARY CARE HOSPITAL: A RETROSPECTIVE ANALYSIS OF PHARMACISTS’ INTERVENTIONS IN CHEMOTHERAPY PREPARATION SERVICES	4CPS-256
	PREOPERATIVE INTRAVENOUS IRON TO TREAT ANEMIA BEFORE MAJOR ORTHOPEDIC SURGERY	4CPS-257
	PHARMACOKINETICS ALTERATIONS IN FIVE CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL	4CPS-258
	MANAGEMENT OF VORICONAZOLE-INDUCED LIVER TOXICITY IN A PEDIATRIC PATIENT	4CPS-259
	PERSISTENCE, SAFETY AND ASSOCIATED LYMPHOPENIA OF DIMETHYL FUMARATE IN RELAPSING REMITTING MULTIPLE SCLEROSIS, REAL WORLD DATA	4CPS-260
	ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ONCOLOGICAL TREATMENT OF PROSTATE CANCER AND CHRONIC MEDICATION.	4CPS-261
	A NOVEL ARTIFICIAL INTELLIGENCE-BASED TOOL TO ASSESS ANTICHOLINERGIC BURDEN: A SURVEY	4CPS-262
	THE PHARMACIST’S ROLE IN OPTIMIZING SURGICAL ANTIBACTERIAL PROPHYLAXIS (SAP)	4CPS-263

Section 5: Patient Safety and Quality Assurance

PDF Document	Poster Title	Poster Number
	EFFICACY AND SAFETY OF THE COMBINATION OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA: A CASE REPORT	5PSQ-001
	PHARMACIST IN SECURING DRUG CIRCUIT : FROM PRESCRIPTION TO ADMINISTRATION (ANALYSIS AND ACTIONS)	5PSQ-002
	PERFORMANCE OF A COLD MAINTENANCE DEVICE DURING THE IMPLEMENTATION OF A PNEUMATIC CIRCUIT	5PSQ-003
	EPCLUSA RELATED SLEEPINESS: A CASE REPORT	5PSQ-004
	ANALYSIS OF ANTI-ANGIOGENESIS-RELATED ADVERSE EVENTS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (VEGFR-TKIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA	5PSQ-005
	IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: A 7-MONTHS ANALYSIS	5PSQ-006
	IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: WHAT’S NEW AND WHAT’S LEFT?	5PSQ-007
	A DIGITAL ASSISTANT TO SUPPORT PATIENTS IN PREPARING MEDICATION RECONCILIATION: PATIENT EXPERIENCES.	5PSQ-008
	EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY SWITCHING IN MIGRAINE PATIENTS	5PSQ-009
	DIGOXIN ADJUSTMENT: COMPARATIVE ANALYSIS OF THREE PHARMACOKINETIC SOFTWARE	5PSQ-010
	PHARMACOKINETIC EVALUATION OF DRUGS WITH A NARROW THERAPEUTIC RANGE AND THEIR INFLUENCE ON CLINICAL DECISION	5PSQ-011
	CASE REPORT: INHALED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR MILD-TO-MODERATE AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS – 24 MONTHS OF FOLLOW-UP	5PSQ-012
	PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: NEUTROPENIA MANAGEMENT IN CLINICAL PRACTICE.	5PSQ-013
	IMPACT OF HISTAMINE-2 ANTAGONIST SHORTAGE ON THE INCIDENCE OF HYPERSENSITIVITY REACTIONS TO PACLITAXEL – TOWARDS CRISIS MANAGEMENT AND A PREMEDICATION RECONSIDERATION IN FRANCE (PACLIREACT STUDY)	5PSQ-014
	PERSISTENCE OF TREATMENT WITH JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN PATIENTS ALREADY TREATED WITH THEM	5PSQ-015
	HUMAN FACTORS ROLE IN MEDICATION ERRORS: DILUTING INTRAVENOUS MEDICATIONS AT HOSPITAL WARDS – A STUDY BASED ON INCIDENT REPORTS	5PSQ-016
	IMMUNE-MEDIATED ADVERSE EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) THERAPY IN REAL LIFE POPULATION: WE CONTINUE TO LEARN.	5PSQ-017
	PRESCRIBING ERRORS IN CHILDREN: WHAT IS THE IMPACT OF A COMPUTERIZED PHYSICIAN ORDER ENTRY?	5PSQ-018
	ANALYSIS OF THE USE OF IDARUCIZUMAB IN A TERTIARY HOSPITAL	5PSQ-019
	ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS TO INCREASE THE SAFETY AND ADEQUACY OF THEIR TREATMENT	5PSQ-020
	AUTOMATION MEETS TRACEABILITY TO OPTIMIZE DRUGS AND MEDICAL DEVICES LOGISTICS GUARANTEEING PATIENT SAFETY AND HOSPITAL STAFF WELL-BEING	5PSQ-021
	ANALYSIS OF HEALTHCARE VISITS TO EMERGENCY SERVICES FROM PATIENTS WITH PAINFUL VASCULAR ULCERS TREATED WITH TOPICAL SEVOFLURANE	5PSQ-022
	SEVERE PHOTOTOXICITY REACTION ASSOCIATED WITH VANDETANIB: A CASE REPORT	5PSQ-023
	HAZARD VULNERABILITY ANALYSIS (HVA): EVALUATION OF RISK IN EXPERIMENTAL ONCOLOGICAL DRUGS COMPOUNDING	5PSQ-024
	IMPACT AND EVALUATION OF PHARMACOKINETIC MONITORING IN PRIMARY CARE.	5PSQ-025
	MEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND CDK4/6 INHIBITORS	5PSQ-026
	APPROPRIATENESS OF PRESCRIPTION OF TRICYCLIC ANTIDEPRESSANTS ACCORDING TO STOPP CRITERIA	5PSQ-027
	CDK 4/6 INHIBITORS – ANALYSIS OF POTENTIAL DRUG INTERACTIONS	5PSQ-028
	PERCEIVED EXPERIENCE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AFTER IMPLEMENTING A TELEPHARMACY PROGRAMME	5PSQ-029
	SAFETY AND SECURITY OF CICLOSPORIN EYE DROPS IN PATIENTS WITH XEROPHTHALMIA	5PSQ-030
	ANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED	5PSQ-031
	PHARMACIST INTEGRATION IN THE MULTIDISCIPLINARY EMERGENCY TEAM	5PSQ-032
	ANTIVIRAL TREATMENT DISCONTINUATION IN PATIENTS WITH HEPATITIS B	5PSQ-033
	FIXED VS WEIGHT-BASED DOSING OF PEMBROLIZUMAB FOR PATIENTS UNDER 80 KG, BASED ON OBSERVED ADRS IN ONE CANCER SETTING	5PSQ-034
	MASS UNIFORMITY OF HARD CAPSULES: ROYAL SPANISH PHARMACOPOEIA VS UNITED STATES PHARMACOPOEIA	5PSQ-035
	MEDICATION ERRORS RELATED TO HIGH-ALERT MEDICATIONS IN A TERTIARY CARE PEDIATRIC HOSPITAL – AN ANALYSIS OF REGISTER-BASED DATA	5PSQ-036
	IMPORTANCE AND IMPACT OF PHARMACEUTICAL RECONCILIATION AT DISCHARGE IN THE ELDERLY PATIENT WITH POLYMEDICATION	5PSQ-037
	DRUG RELATED VISITS TO THE EMERGENCY DEPARTMENT IN NURSING HOME PATIENTS	5PSQ-038
	RAF-KINASI PATHWAY INHIBITORS IN TREATMENT OF METASTATIC MELANOMA: WHEN COMPLIANCE DOESN’T MATCH WITH TOLERANCE.	5PSQ-039
	ANALYSIS OF THE IMPACT OF THE COVID-19 PANDEMIC ON PSYCHOTROPIC DRUG USE	5PSQ-040
	STERILE INTRAOCULAR INFLAMMATION AFTER INTRAVITREAL AFLIBERCEPT	5PSQ-041
	PREVALENCE OF MEDICATION PRESCRIPTION WITH A POTENTIAL NEGATIVE EFFECT ON SWALLOWING IN OUTPATIENTS WITH COGNITIVE IMPAIRMENT AND A DIAGNOSIS OF DYSPHAGIA.	5PSQ-042
	UNSUPPORTED PRESCRIPTION OF POLYVALENT IMMUNOGLOBULINS IN A UNIVERSITY HOSPITAL CENTER: FREQUENCY AND COST	5PSQ-043
	REAL-LIFE SAFETY AND SATISFACTION OF CFTR PROTEIN MODULATORS IN CYSTIC FIBROSIS	5PSQ-044
	IMPACT OF PHARMACEUTICAL INTERVENTIONS IN CRITICAL PATIENTS	5PSQ-045
	FMEA (FAILURE MODE AND EFFECT ANALYSIS) APPLICATION TO PARENTERAL NUTRITION BAGS MANUFACTURING PROCESS: ROLE OF HOSPITAL PHARMACIST	5PSQ-046
	PRECAUTIONARY CANCELLATION: TOOL TO IMPROVE PATIENT SAFETY	5PSQ-047
	WHAT DO ONCOLOGISTS AND PHARMACISTS THINK AND WANT FROM A CAHM-DRUG INTERACTION CHECKER? A BROADSCALE SURVEY TO ASSESS EXPECTATIONS.	5PSQ-048
	ASSESSMENT AND OPTIMISATION OF THE MANAGEMENT OF HIGH RISK MEDICINES IN A GENERAL HOSPITAL	5PSQ-049
	ANALYSIS OF THE USE OF USTEKINUMAB FOR CROHN DISEASE IN THE REAL CLINICAL PRACTICE	5PSQ-050
	PARKINSONISM INDUCED BY TAKING TRAZODONE AS A HYPNOTIC: A CASE REPORT	5PSQ-051
	CHANGES IN POLYMEDICATED PATIENTS’ PRESCRIPTIONS AFTER OUTPATIENT HOSPITAL CONSULTATIONS IN REAL LIFE SITUATIONS	5PSQ-052
	DESIGN OF A PRIORIZATION SYSTEM BY COMPLEXITY OF THE REVIEW IN POLYMEDICATED PATIENTS: POTENTIAL INADECUACY INDEX	5PSQ-053
	ASSESSEMENT OF OCCUPATIONAL PRACTICES: ANALYSIS OF THE PRESCRIPTIONS OF TRANSCATHETER AORTICVALVE IMPLANTATION (TAVI)	5PSQ-054
	SAFETY TESTING ASSESSMENT FOR THE ADHERENCE OF DOSE REDUCTION IN ONCOLOGY TREATMENT FOLLOWING CLINICAL GUIDELINES RECOMMENDATIONS IN PATIENTS PRIOR RECEIVING FLUOROPYRIMIDINES (5-FLUOROURACIL, CAPECITABINE AND TEGAFUR)	5PSQ-055
	HETEROGENEITY OF DEXMEDETOMIDINE TREATMENT EFFECT ON MORTALITY ACCORDING TO AGE	5PSQ-056
	EFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF INFLAMMATORY FACIAL GRANULOMA SECONDARY TO SILICONE	5PSQ-057
	MANAGEMENT OF SOLID ORAL PHARMACEUTICAL FORMS WITH UNIT DOSE	5PSQ-058
	REAL-WORLD CLINICAL DATA OF PALBOCICLIB AND RIBOCICLIB IN BREAST CANCER PATIENT	5PSQ-059
	GLUTEN IN MEDICINES. A PRESCRIPTION HELPING TOOL.	5PSQ-060
	NEW-ONSET MULTIPLE SCLEROSIS ASSOCIATED WITH ADALIMUMAB TREATMENT: ABOUT TWO CASE REPORTS	5PSQ-061
	REVIEW AND DEPRESCRIPTION OF MEDICATION IN POLYMEDICATED PATIENTS WITH PSYCHOACTIVE DRUGS.	5PSQ-062
	A CROSS-SECTIONAL STUDY ON THE POTENTIALLY INAPROPIATE PRESCRIBED AND CONTRAINDICATED HIGH-RISK MEDICATION IN HOSPITALIZED CHRONIC COMPLEX PATIENTS	5PSQ-063
	CONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT	5PSQ-064
	BE A HUMAN, NOT A CASE REPORT! HOSPITAL PHARMACISTS MAKE THE DIFFERENCE	5PSQ-065
	ADEQUACY TO PROTOCOL OF USE OF TOCILIZUMAB FOR MANAGEMENT OF COVD-19 DISEASE	5PSQ-066
	TRACKING THE OVERAL IN USE AND STRESS STABILITY OF ROMIPLISTIM (N-PLATE®) BY THE EVALUATION OF A SELECTED SET OF CRITICAL QUALITY ATTRIBUTES	5PSQ-067
	DIARRHEA OCCURRENCE ANALYSIS IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS	5PSQ-068
	ANALYSIS AND MONITORING OF ERRORS ASSOCIATED WITH ELECTRONIC PRESCRIPTION SYSTEMS: PRESCRIPTIONS WITH INCORRECT DRUG SCHEDULES.	5PSQ-069
	PHARMACEUTICAL CARE IN AN ONCO-HEMATOLOGICAL CLINICAL TRIALS UNIT	5PSQ-070
	ANALYSIS OF MEDICATION PROVIDED BY PATIENTS	5PSQ-071
	ANALYSIS OF THE DURATION AND COMPLICATIONS ASSOCIATED WITH PERIPHERAL PARENTERAL NUTRITION: A COHORT STUDY.	5PSQ-072
	IS THERE A SAFETY DIFFERENCE? JANUS KINASE INHIBITORS IN REAL CLINICAL PRACTICE	5PSQ-073
	INTERACTIONS DETECTED WITH THE USE OF NIRMATRELVIR/RITONAVIR IN A TERTIARY HOSPITAL	5PSQ-074
	PROPOSAL FOR THE ADJUSTMENT AND OPTIMISATION OF THE MEDICATION PROVIDED BY THE PATIENT	5PSQ-075
	PATIENTS’ SATISFACTION AFTER CHANGING FROM 150MG TO 300MG SECUKINUMAB PEN PRESENTATION	5PSQ-076
	CYCLIN DEPENDENT KINASES 4 AND 6 INHIBITORS – REAL-WORLD DATA ANALYSIS	5PSQ-077
	ANALYSIS OF CASIRIVIMAB AND IMDEVIMAB USE IN OUTPATIENTS WITH COVID-19	5PSQ-078
	FONDAPARINUX IN AN INFANT WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA. A CASE REPORT.	5PSQ-079
	IDENTIFICATION OF PHARMACOLOGICAL INTERACTIONS BETWEEN IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND DIETARY SUPPLEMENTS/HERBS IN PATIENTS WITH CYSTIC FIBROSIS IN AN OUTPATIENT PHARMACEUTICAL CARE UNIT	5PSQ-080
	ASSESSMENT OF THE IMPACT OF THE PHARMACEUTICAL INTERVENTION IN MEDICATION RECONCILIATION AT PATIENT ADMISSION IN A SURGICAL PRE-HOSPITALIZATION CLINIC	5PSQ-081
	GRAVIMETRIC CONTROL OF PARENTERAL NUTRITION IN NEONATOLOGY AND PEDIATRICS.	5PSQ-082
	FOUR YEARS OF A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY	5PSQ-083
	ASSESSING QUALITY OF LIFE OF PATIENTS WITH SEVERE ASTHMA MEASURED BY PATIENT REPORTED OUTCOMES	5PSQ-084
	MEDICATION ADMINISTRATION IN PATIENTS WITH DYSPHAGIA: SEARCHING FOR THE BEST PHARMACEUTICAL FORM	5PSQ-085
	ANALYSIS OF POTENCIALLY INAPPROPRIATE PRESCRIPTION IN A NURSING HOME	5PSQ-086
	EVALUATION OF THE EFFECTIVENESS OF LAMIVUDINE IN THE PROPHYLAXIS OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL DISEASES	5PSQ-087
	EXPLORING THE NEED FOR A CHECK OF COMPOUNDING APPROPRIATENESS SERVICE: EVALUATION OF SPONTANEOUS CHECKS BEFORE COMPOUNDING AT A LARGE TERTIARY CARE HOSPITAL	5PSQ-088
	CHRONIC NON-CANCER PAIN, WHAT ABOUT THIS PATIENTS?	5PSQ-089
	STUDY OF THE USE OF RESTRICTED ANTIBIOTICS DURING COVID-19 PANDEMIC: CEFTAROLINE, CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM.	5PSQ-090
	TRIFECTA™ BIOPROSTHESES : EVALUATION OF THE SAFETY BASED ON THE STUDY OF DEGENERATIONS ACCORDING TO THE VARC-3 CLASSIFICATION	5PSQ-091
	PHARMACOVIGILANCE OF BIOLOGICAL THERAPIES FROM THE OUTPATIENT DEPARTMENT	5PSQ-092
	PHARMACEUTICAL INTERVENTION AFTER INAPPROPRIATE PRESCRIPTION OF ZOLPIDEM	5PSQ-093
	TOXICITY IN PATIENTS TREATED WITH VENETOCLAX. A SAFETY STUDY IN REAL-WORLD PRACTICE	5PSQ-094
	CARDIAC CONDUCTION DISORDERS ASSOCIATED WITH THE USE OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY	5PSQ-095
	A PROSPECTIVE OBSERVATIONAL STUDY OF MEDICATION PRESCRIBING ERRORS IN AN EMERGENCY DEPARTMENT.	5PSQ-096
	HEALTH ALERT OF TOFACITINIB AND PHARMACEUTICAL INTERVENTION	5PSQ-097
	SAFETY AND PERSISTENCE OF ANTI-FIBROTIC DRUGS IN INTERSTITIAL LUNG DISEASES	5PSQ-098
	ADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARS-CoV-2 INFECTION IN A UNIVERSITY HOSPITAL	5PSQ-099
	UTILITY OF SOCIAL MEDIA AS A SOURCE OF PAEDIATRIC DRUG SAFETY, A SYSTEMATIC REVIEW	5PSQ-100
	ANALYSIS OF HIP PROSTHESES OVER A YEAR	5PSQ-101
	SAFETY EVALUATION OF MIDLINE CATHETERS USED FOR ANTIBIOTIC THERAPY	5PSQ-102
	PARENTAL UNMET NEEDS ON PAEDIATRIC DRUGS EXPRESSED IN FORUMS	5PSQ-103
	ERRORS IN ACENOCOUMAROL RECONCILIATION IN PATIENTS ADMITTED FROM THE EMERGENCY DEPARTMENT	5PSQ-104
	DEVELOPMENT OF HYPOMAGNESEMIA IN CRITICAL PATIENTS TREATED WITH ISAVUCONAZOLE	5PSQ-105
	SAFETY PERCEIVED BY PROFESSIONALS AFTER THE INNOVATION OF THE MEDICATION USE CIRCUIT IN A NEONATAL INTENSIVE CARE UNIT	5PSQ-106
	SAFETY ASSESSMENT OF ERENUMAB AND GALCANEZUMAB IN CLINICAL PRACTICE	5PSQ-107
	COMPUTERIZED PHYSICIAN ORDER ENTRY WITH CLINICAL DECISION SUPPORT IN PREVENTING WRONG DOSE ERRORS IN PEDIATRIC MEDICATION ORDERS: A SYSTEMATIC REVIEW	5PSQ-108
	RANSOMWARE ATTACK ON A CYTOTOXIC PREPARATION UNIT (CPU): WHAT NOW?	5PSQ-109
	IMPACT OF THE USE OF TRANSPARENT ADHESIVE DRESSINGS ON INFECTIONS IN PERITONEAL DIALYSIS	5PSQ-110
	MEDICATION ERRORS, THEIR PERCEPTION, ANALYSIS, AND PROPOSAL OF SOLUTIONS IN A PUBLIC HOSPITAL	5PSQ-111
	RELATIONSHIP BETWEEN EFFECTIVENESS AND IMMUNE-MEDIATED TOXICITY OF IMMUNE CHECK-POINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER	5PSQ-112
	REAL-LIFE EFFECTIVENESS, SAFETY AND ADHERENCE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS	5PSQ-113
	PERSISTENCE AND LEVEL OF CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH GUSELKUMAB	5PSQ-114
	DEPRESCRIBING LONG-TERM TREATMENTS WITH BIPHOSPHONATES. PHARMACEUTICAL INTERVENTION BRINGS VALUE.	5PSQ-115
	PERSISTENCE OF INHIBITORS OF INTERLEUKIN-23 (anti-IL-23) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (msPs) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS.	5PSQ-116
	EVALUATION OF CARDIOTOXICITY BY OSIMERTINIB IN CLINICAL PRACTICE	5PSQ-117
	PATIENTS´ EXPERIENCE WITH SUBCUTANEOUS INJECTION SELF-ADMINISTRATION AND THE ROLE OF VIRTUAL REALITY	5PSQ-118
	A NEW PHARMACEUTICAL CARE PROGRAMME FOR COVID-19 PATIENTS TREATED WITH PAXLOVID® : IMPLEMENTATION AND SAFETY OUTCOMES REPORTED	5PSQ-119
	ANALYSIS OF THE PHARMACEUTICAL INTERVENTIONS PERFORMED ON ONCOHEMATOLOGICAL PATIENTS THROUGH AN ONCOHEMATOLOGY PHARMACY CONSULTATION	5PSQ-120
	CYTOKINE RELEASE SYNDROME RELATED TO THE TREATMENT WITH TECLISTAMAB: A CASE REPORT	5PSQ-121
	COVID-19 VACCINE VIGILANCE: COMPARATIVE STUDY BETWEEN HOSPITAL, REGIONAL AND NATIONAL DATA	5PSQ-122
	IMPACT OF PHARMACOTHERAPEUTIC COMPLEXITY ON ADHERENCE TO ANTIRETROVIRAL TREATMENT IN OLDER ADULTS WITH HIV	5PSQ-123
	EFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL TREATMENT SIMPLIFICATION TO DOLUTEGRAVIR+LAMIVUDINE OR DOLUTEGRAVIR+RILPIVIRINE IN OLDER ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS	5PSQ-124
	BRIDGING ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER A TRANSURETHRAL RESECTION: PATIENT MANAGEMENT IS DONE APPROPRIATELY?	5PSQ-125
	EFFICACY AND SAFETY OF OMALIZUMAB, MEPOLIZUMAB AND BENRALIZUMAB IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA	5PSQ-126
	PHARMACOLOGICAL RISK FACTORS FOR DRUG-DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV: A SYSTEMATIC REVIEW	5PSQ-127
	THROMBOPROPHYLAXIS IN THE EMERGENCY DEPARTMENT. ADEQUACY OF THE PRESCRIPTION.	5PSQ-128
	SWITCHING BETWEEN ANTI-CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN MIGRAINE	5PSQ-129
	OFF-LABEL USE OF CIDOFOVIR INTRALESIONAL INJECTIONS IN EXTENSIVE ANOGENITAL CONDYLOMATOSIS: A CASE REPORT	5PSQ-130
	LETERMOVIR, GANCICLOVIR AND IMMUNOGLOBULINS COMBINATION TREATMENT IN AN IMMUNOCOMPROMISED PATIENT WITH CYTOMEGALOVIRUS INFECTION: A CASE REPORT	5PSQ-131
	PHARMACOGENETIC-GUIDED TREATMENT IN PATIENTS WITH DYHYDROPIRYMIDINE DEHYDROGENASE DEFICIENCY	5PSQ-132
	PHARMACISTS – GENERAL PRACTIONERS (GPs) COLLABORATION TO IDENTIFY DRUG-RELATED PROBLEMS (DRPs) IN PATIENTS IN POLYTHERAPY	5PSQ-133
	UNIT DOSE IN A CYBERATTACK SCENARIO	5PSQ-134
	HAS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME HAD AN IMPACT ON THE ANTIBIOTIC CONSUMPTION?	5PSQ-135
	ANALYSIS OF ANTIRETROVIRAL THERAPY POTENCY IN HIV- NAÏVE PATIENTS	5PSQ-136
	ANALYSIS OF THE DPYD GENE MUTATIONS IN CANCER PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH FLUOROPYRIMIDINES	5PSQ-137
	CHEMOTHERAPY ERRORS DETECTED DURING PHARMACEUTICAL VALIDATION	5PSQ-138
	USING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs)	5PSQ-139
	FREQUENCY OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS UNDERGOING HOME TREATMENT WITH DIRECT-ACTING ORAL ANTICOAGULANTS (DOACs)	5PSQ-140
	FALLS IN ELDERLY PATIENTS AND CHRONIC CONSUMPTION OF ANXIOLYTIC BENZODIAZEPINES.	5PSQ-141
	EVALUATION OF ADEQUACY, ADHERENCE AND SAFETY OF HUMAN IMMUNODEFICIENCY VIRUS POST-EXPOSURE TREATMENT	5PSQ-142
	THE ROLE OF THE PHARMACIST IN INCREASING HEALTH VIGILANCE AMONG HEALTH PROFESSIONALS: QUINCKE’S EDEMA FOLLOWING THE ADMINISTRATION OF RITUXIMAB	5PSQ-143
	ELECTRONIC PATIENT-REPORTED OUTCOME (PROM) MEASUREMENT USING PRO-CTCAE®QUESTIONNAIRE TO IMPROVE QUALITY OF LIFE ASSESSMENT AND HEALTHCARE RESOURCES MANAGEMENT IN PATIENTS WITH LYMPHOMA RECEIVING INTRAVENOUS CHEMOTHERAPY	5PSQ-144
	A PATIENT SATISFACTION SURVEY ON UNIT DOSE DRUG DISTRIBUTION IN HOSPITAL	5PSQ-145

Section 6: Education and Research

PDF Document	Poster Title	Poster Number
	THE USE OF GAMIFICATION TO EVALUATE PUBLIC UNDERSTANDING OF ADVERSE DRUG REACTIONS	6ER-001
	WHAT’s ANOTHER PEER? EXPLORING THE USE OF NEAR PEER TEACHING OF MEDICATION HISTORY TAKING IN PHARMACY UNDERGRADUATES IN THE UK	6ER-002
	THE CLIMATE EMERGENCY, HOW CAN PHARMACY MAKE A DIFFERENCE?	6ER-003
	EFFECTIVENESS AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED DISEASES ON BIOLOGICAL THERAPY	6ER-004
	EFFECTS OF ADHERENCE TO THE MEDITERRANEAN DIET IN PATIENTS WITH AUTOIMMUNE DISEASES	6ER-005
	CURRENT PERFORMANCE OF HOSPITAL PHARMACY SPECIALISTS TRAINED AT A TERTIARY HOSPITAL IN SPAIN	6ER-006
	PHYSICO-CHEMICAL PARAMETERS OF TOBACCO OIL AND PREPARATION OF A DOSAGE FORM BASED ON IT	6ER-007
	CORRELATES OF ONE-YEAR MORTALITY AMONG PATIENTS LIVING WITH HIV ACCORDING TO THE STRATIFICATION LEVEL OF THE PHARMACEUTICAL CARE MODEL	6ER-008
	COMPARATIVE EFFICACY OF ABEMACICLIB AND PALBOCICLIB AS ADJUVANT TREATMENT IN PATIENTS WITH EARLY BREAST CANCER	6ER-009
	EVOLUTION OF ONCOHAEMATOLOGICAL CLINICAL TRIALS FROM 2016 TO 2021: EXPERIENCE FROM A TERTIARY HOSPITAL	6ER-010
	EFFICACY OF THERAPIES IN NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS: A SYSTEMATIC REVIEW	6ER-011
	TREATMENT DECISIONS ACCORDING TO 1-YEAR RISK MORTALITY IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY.	6ER-012
	1 YEAR-MORTALITY RISK ASSESSMENT IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY.	6ER-013
	EFFECTIVENESS AND SAFETY OF THE ADMINISTRATION OF MURPHY’S ENEMA FOR THE TREATMENT OF REFRACTORY CONSTIPATION IN A TERTIARY HOSPITAL	6ER-014
	AZACITIDINE IN THE TREATMENT OF JUVENILE MYELOMONOCYTIC LEUKAEMIA: AN UP-TO-DATE PHARMACY PROTOCOL	6ER-015
	IDENTIFICATION OF NEW GENES OF EARLY RESPONSE TO ANTI-TNFS BY RNASEQ IN PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.	6ER-016
	STRUCTURED OBJECTIVE CLINICAL EVALUATION FOR PHARMACY STUDENTS ON INTERNSHIPS AT THE HOSPITAL	6ER-017
	OFF-LABEL USE OF USTEKINUMAB IN REFRACTORY EPIDERMOLYTIC ICHTHYOSIS: A CASE REPORT	6ER-018
	THE STUDENT PHARMACIST EXPERIENCE OF ENHANCED CLINICAL PLACEMENTS	6ER-019
	PRESCRIPTION AND USE OF LIPOSOMAL AMPHOTERICIN B DURING THE COVID-19 PANDEMIC	6ER-020
	RETROSPECTIVE OF DRUG INNOVATION DURING THE SARS-Cov2 PANDEMIC : DEVELOPMENT OF A GAME-BASED TRAINING	6ER-021
	CLINICAL IMPACT OF THE USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF COVID-19 IN INTERMEDIATE RESPIRATORY CARE UNITS	6ER-022
	THE ASSOCIATION BETWEEN NADROPARIN DOSE AND ANTI-XA LEVELS IN RENAL INSUFFICIENCY: A MULTICENTER STUDY	6ER-023
	COMPARISON OF REDUCTIONS IN MONTHLY MIGRAINE DAYS BETWEEN NEW SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS (GEPANTS) AND MONOCLONAL ANTIBODIES TARGETING CGRP/CGRP RECEPTOR	6ER-024
	EFECTIVENESS AND SAFETY OF 20% AUTOLOGOUS SERUM EYE DROPS IN PATIENTS WITH CORNEAL SURFACE PATHOLOGIES	6ER-025
	SPECTRUM OF HEART FAILURE IN 16 SUB-SAHARAN AFRICAN COUNTRIES: TREATMENTS AND IN-HOSPITAL OUTCOME	6ER-026
	ASSESSMENT OF ATTITUDES AND PERCEIVED SKILLFULNESS OF PHARMACY STUDENTS IN CARING FOR UNDERSERVED POPULATIONS	6ER-027
	ASSESSMENT OF SYMPTOMS AND SIGNS SEVERITY IN PSORIASIS PATIENTS	6ER-028
	EYE DROPS OF INTERFERON ALPHA-2B TO TREAT OCULAR PATHOLOGIES	6ER-029
	USING A PHARMACIST-LED ASTHMA SERVICE TO ASSESS THE CONCORDANCE BETWEEN PATIENT-REPORTED ICS ADHERENCE AND OBJECTIVE E-MONITORING OF ICS THERAPY	6ER-030
	KWOLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION IN PEOPLE LIVING WITH HIV IN ANTIRETROVIRAL THERAPY	6ER-031
	HOW CAN DUTCH UNIVERSITY HOSPITALS CONTRIBUTE TO AFFORDABLE MEDICINES AND COST CONTAINMENT OF TOTAL HOSPITAL DRUG EXPENDITURE: A DELPHI STUDY	6ER-032
	PEMBROLIZUMAB AND ATEZOLIZUMAB AS POSSIBLE EQUIVALENT FIRST-LINE THERAPEUTIC ALTERNATIVES IN PDL1-EXPRESSING TRIPLE-NEGATIVE BREAST CANCER	6ER-033
	USE OF CLOSED SYSTEM TRANSFER DEVICES WITH INVESTIGATIONAL DRUG PRODUCTS	6ER-034